Respiratory syncytial virus: Infection, detection, and new options for prevention and treatment

Clinical Microbiology Reviews

Volumn 30, Issue 1, 2017, Pages 277-319

  Griffiths, Cameron ^a   Drews, Steven J ^b,c   Marchant, David J ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Diagnostics; Epidemiology; Experimental therapeutics; Immunization; Respiratory syncytial virus; Viral pathogenesis

Indexed keywords

4' CHLOROMETHYL 2' DEOXY 2' FLUOROCYTIDINE 3',5' DIISOBUTYRATE; CHEMOKINE RECEPTOR CX3CR1; EMODIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLAVONOID; HEAT SHOCK PROTEIN 70; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 33; LIPOCORTIN 2; MOTAVIZUMAB; NUCLEOLIN; PALIVIZUMAB; PRESATOVIR; PROTEOHEPARAN SULFATE; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; SILVER NANOPARTICLE; TOLL LIKE RECEPTOR 4; ANTIVIRUS AGENT; VIRUS VACCINE;

AIRWAY RESISTANCE; ARTICLE; ASTHMA; BONE MARROW TRANSPLANTATION; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DISEASE PREDISPOSITION; ENZYME IMMUNOASSAY; GENE REPLICATION; GENE SEQUENCE; HEALTH CARE COST; HOSPITAL ADMISSION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPROMISED PATIENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; RESPIRATORY TRACT INFLAMMATION; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; VACCINATION; VIRUS TRANSCRIPTION; VIRUS TRANSMISSION; HUMAN RESPIRATORY SYNCYTIAL VIRUS; PATHOGENICITY; POINT OF CARE SYSTEM; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VIRULENCE;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; POINT-OF-CARE SYSTEMS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL VACCINES; VIRULENCE;

EID: 85007227794     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00010-16     Document Type: Article

References (371)

1. Blount RE, Jr, Morris JA, Savage RE. 1956. Recovery of cytopathogenic agent from chimpanzees with coryza. Proc Soc Exp Biol Med 92: 544-549. https://doi.org/10.3181/00379727-92-22538.
2. Chanock R, Roizman B, Myers R. 1957. Recovery from infants with respiratory illness of a virus related to chimpanzee coryza agent (CCA). I. Isolation, properties and characterization. Am J Hyg 66: 281-290.
3. Hall CB. 2001. Respiratory syncytial virus and parainfluenza virus. N Engl J Med 344: 1917-1928. https://doi.org/10.1056/NEJM200106213442507.
4. Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. 2009. The burden of respiratory syncytial virus infection in young children. N Engl J Med 360: 588-598. https://doi.org/10.1056/ NEJMoa0804877.
5. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352: 1749-1759. https://doi.org/10.1056/NEJMoa043951.
6. Falsey AR, Walsh EE. 2005. Respiratory syncytial virus infection in elderly adults. Drugs Aging 22: 577-587. https://doi.org/10.2165/00002512-200522070-00004.
7. Morales F, Calder MA, Inglis JM, Murdoch PS, Williamson J. 1983. A study of respiratory infections in the elderly to assess the role of respiratory syncytial virus. J Infect 7: 236-247. https://doi.org/10.1016/ S0163-4453(83)97142-6.
8. Sorvillo FJ, Huie SF, Strassburg MA, Butsumyo A, Shandera WX, Fannin SL. 1984. An outbreak of respiratory syncytial virus pneumonia in a nursing home for the elderly. J Infect 9: 252-256. https://doi.org/10.1016/S0163-4453(84)90530-9.
9. Han LL, Alexander JP, Anderson LJ. 1999. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis 179: 25-30. https://doi.org/10.1086/314567.
10. Fulginiti VA, Eller JJ, Sieber OF, Joyner JW, Minamitani M, Meiklejohn G. 1969. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89: 435-448.
11. Kim HW, Canchola JG, Brandt CD, Pyles G, Chanock RM, Jensen K, Parrott RH. 1969. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89: 422-434.
12. Delgado MF, Coviello S, Monsalvo AC, Melendi GA, Hernandez JZ, Batalle JP, Diaz L, Trento A, Chang HY, Mitzner W, Ravetch J, Melero JA, Irusta PM, Polack FP. 2009. Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med 15: 34-41. https://doi.org/10.1038/ nm.1894.
13. Gower TL, Pastey MK, Peeples ME, Collins PL, McCurdy LH, Hart TK, Guth A, Johnson TR, Graham BS. 2005. RhoA signaling is required for respiratory syncytial virus-induced syncytium formation and filamentous virion morphology. J Virol 79: 5326-5336. https://doi.org/10.1128/ JVI.79.9.5326-5336.2005.
14. Knipe DM, Howley PM, Cohen JI, Griffin DE, Lamb RA, Martin MA, Racaniello VR, Roizman B (ed). 2013. Fields virology, 6th ed. Lippincott Williams & Wilkins, Philadelphia, PA.
15. Agoti CN, Otieno JR, Gitahi CW, Cane PA, Nokes DJ. 2014. Rapid spread and diversification of respiratory syncytial virus genotype ON1, Kenya. Emerg Infect Dis 20: 950-959. https://doi.org/10.3201/eid2006.131438.
16. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O’Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375: 1545-1555. https://doi.org/10.1016/S0140-6736(10)60206-1.
17. Byington CL, Wilkes J, Korgenski K, Sheng X. 2015. Respiratory syncytial virus-associated mortality in hospitalized infants and young children. Pediatrics 135: e24-e31. https://doi.org/10.1542/peds.2014-2151.
18. Walsh EE, Falsey AR. 2012. Respiratory syncytial virus infection in adult populations. Infect Disord Drug Targets 12: 98-102. https://doi.org/10.2174/187152612800100116.
19. Ramirez JA. 2008. RSV infection in the adult population. Manag Care 17(11 Suppl 12): 13-15.
20. Pilie P, Werbel WA, Riddell J, IV, Shu X, Schaubel D, Gregg KS. 2015. Adult patients with respiratory syncytial virus infection: impact of solid organ and hematopoietic stem cell transplantation on outcomes. Transpl Infect Dis 17: 551-557. https://doi.org/10.1111/tid.12409.
21. Shah JN, Chemaly RF. 2011. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 117: 2755-2763. https://doi.org/10.1182/blood-2010-08-263400.
22. Robinson JL, Grenier D, MacLusky I, Allen UD. 2015. Respiratory syncytial virus infections in pediatric transplant recipients: a Canadian Paediatric Surveillance Program study. Pediatr Transplant 19: 659-662. https://doi.org/10.1111/petr.12553.
23. Pelaez A, Lyon GM, Force SD, Ramirez AM, Neujahr DC, Foster M, Naik PM, Gal AA, Mitchell PO, Lawrence EC. 2009. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant 28: 67-71. https://doi.org/10.1016/j.healun.2008.10.008.
24. Burrows FS, Carlos LM, Benzimra M, Marriott DJ, Havryk AP, Plit ML, Malouf MA, Glanville AR. 2015. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efficiency. J Heart Lung Transplant 34: 958-962. https://doi.org/10.1016/j.healun.2015.01.009.
25. Avetisyan G, Mattsson J, Sparrelid E, Ljungman P. 2009. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation 88: 1222-1226. https://doi.org/10.1097/ TP.0b013e3181bb477e.
26. Langley JM, Wang EE, Law BJ, Stephens D, Boucher FD, Dobson S, McDonald J, MacDonald NE, Mitchell I, Robinson JL. 1997. Economic evaluation of respiratory syncytial virus infection in Canadian children: a Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) study. J Pediatr 131: 113-117. https://doi.org/10.1016/S0022-3476(97)70133-1.
27. Paramore LC, Ciuryla V, Ciesla G, Liu L. 2004. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22: 275-284. https://doi.org/10.2165/00019053-200422050-00001.
28. Falsey AR, Formica MA, Hennessey PA, Criddle MM, Sullender WM, Walsh EE. 2006. Detection of respiratory syncytial virus in adults with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173: 639-643. https://doi.org/10.1164/rccm.200510-1681OC.
29. Jain S, Williams DJ, Arnold SR, Ampofo K, Bramley AM, Reed C, Stockmann C, Anderson EJ, Grijalva CG, Self WH, Zhu Y, Patel A, Hymas W, Chappell JD, Kaufman RA, Kan JH, Dansie D, Lenny N, Hillyard DR, Haynes LM, Levine M, Lindstrom S, Winchell JM, Katz JM, Erdman D, Schneider E, Hicks LA, Wunderink RG, Edwards KM, Pavia AT, McCullers JA, Finelli L, CDC EPIC Study Team. 2015. Community-acquired pneumonia requiring hospitalization among U.S. children. N Engl J Med 372: 835-845. https://doi.org/10.1056/NEJMoa1405870.
30. Hislop AA. 2002. Airway and blood vessel interaction during lung development. J Anat 201: 325-334. https://doi.org/10.1046/j.1469-7580.2002.00097.x.
31. Ostadabbas S, Bulach C, Ku DN, Anderson LJ, Ghovanloo M. 2014. A passive quantitative measurement of airway resistance using depth data. Conf Proc IEEE Eng Med Biol Soc 2014: 5743-5747. https://doi.org/10.1109/EMBC.2014.6944932.
32. Goetzl EJ. 1980. Mediators of immediate hypersensitivity derived from arachidonic acid. N Engl J Med 303: 822-825. https://doi.org/10.1056/ NEJM198010023031421.
33. James AL, Pare PD, Hogg JC. 1989. The mechanics of airway narrowing in asthma. Am Rev Respir Dis 139: 242-246. https://doi.org/10.1164/ ajrccm/139.1.242.
34. Hennessy AV. 1962. An attempt to demonstrate a viral etiology for chronic bronchitis. Am Rev Respir Dis 86: 350-352.
35. Schroeckenstein DC, Busse WW. 1988. Viral "bronchitis" in childhood: relationship to asthma and obstructive lung disease. Semin Respir Infect 3: 40-48.
36. Monto AS. 1995. Epidemiology of respiratory viruses in persons with and without asthma and COPD. Am J Respir Crit Care Med 151: 1653-1657. https://doi.org/10.1164/ajrccm/151.5_Pt_1.1653.
37. Hegele RG, Hayashi S, Hogg JC, Pare PD. 1995. Mechanisms of airway narrowing and hyperresponsiveness in viral respiratory tract infections. Am J Respir Crit Care Med 151: 1659-1664. https://doi.org/10.1164/ ajrccm.151.5.7735630.
38. Vannella KM, Moore BB. 2008. Viruses as co-factors for the initiation or exacerbation of lung fibrosis. Fibrogenesis Tissue Repair 1: 2. https:// doi.org/10.1186/1755-1536-1-2.
39. Vannella KM, Luckhardt TR, Wilke CA, van Dyk LF, Toews GB, Moore BB. 2010. Latent herpesvirus infection augments experimental pulmonary fibrosis. Am J Respir Crit Care Med 181: 465-477. https://doi.org/10.1164/rccm.200905-0798OC.
40. Drysdale SB, Lo J, Prendergast M, Alcazar M, Wilson T, Zuckerman M, Smith M, Broughton S, Rafferty GF, Peacock JL, Johnston SL, Greenough A. 2014. Lung function of preterm infants before and after viral infections. Eur J Pediatr 173: 1497-1504. https://doi.org/10.1007/s00431-014-2343-1.
41. Jackson DJ, Makrinioti H, Rana BM, Shamji BW, Trujillo-Torralbo MB, Footitt J, Jerico D-R, Telcian AG, Nikonova A, Zhu J, Aniscenko J, Gogsadze L, Bakhsoliani E, Traub S, Dhariwal J, Porter J, Hunt D, Hunt T, Hunt T, Stanciu LA, Khaitov M, Bartlett NW, Edwards MR, Kon OM, Mallia P, Papadopoulos NG, Akdis CA, Westwick J, Edwards MJ, Cousins DJ, Walton RP, Johnston SL. 2014. IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 190: 1373-1382. https://doi.org/10.1164/rccm.201406-1039OC.
42. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. 2005. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490. https://doi.org/10.1016/j.immuni.2005.09.015.
43. Chen Y, Williams E, Kirk M. 2014. Risk factors for acute respiratory infection in the Australian community. PLoS One 9: e101440. https:// doi.org/10.1371/journal.pone.0101440.
44. Okiro EA, Ngama M, Bett A, Cane PA, Medley GF, James Nokes D. 2008. Factors associated with increased risk of progression to respiratory syncytial virus-associated pneumonia in young Kenyan children. Trop Med Int Health 13: 914-926. https://doi.org/10.1111/j.1365-3156.2008.02092.x.
45. Weber MW, Milligan P, Hilton S, Lahai G, Whittle H, Mulholland EK, Greenwood BM. 1999. Risk factors for severe respiratory syncytial virus infection leading to hospital admission in children in the Western Region of The Gambia. Int J Epidemiol 28: 157-162. https://doi.org/10.1093/ije/28.1.157.
46. Wu A, Budge PJ, Williams J, Griffin MR, Edwards KM, Johnson M, Zhu Y, Hartinger S, Verastegui H, Gil AI, Lanata CF, Grijalva CG. 2015. Incidence and risk factors for respiratory syncytial virus and human metapneumovirus infections among children in the remote highlands of Peru. PLoS One 10: e0130233. https://doi.org/10.1371/journal.pone.0130233.
47. Cilla G, Sarasua A, Montes M, Arostegui N, Vicente D, Perez-Yarza E, Perez-Trallero E. 2006. Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain. Epidemiol Infect 134: 506-513. https://doi.org/10.1017/ S0950268805005571.
48. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. 2000. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283: 499-505. https://doi.org/10.1001/jama.283.4.499.
49. Mori M, Morio T, Ito S, Morimoto A, Ota S, Mizuta K, Iwata T, Hara T, Saji T. 2014. Risks and prevention of severe RS virus infection among children with immunodeficiency and Down’s syndrome. J Infect Chemother 20: 455-459. https://doi.org/10.1016/j.jiac.2014.05.001.
50. Fixler DE. 1996. Respiratory syncytial virus infection in children with congenital heart disease: a review. Pediatr Cardiol 17: 163-168. https:// doi.org/10.1007/BF02505206.
51. Anonymous. 1987. American Academy of Pediatrics Committee on Infectious Diseases: ribavirin therapy of respiratory syncytial virus. Pediatrics 79: 475-478.
52. Lee YI, Peng CC, Chiu NC, Huang DT, Huang FY, Chi H. 2016. Risk factors associated with death in patients with severe respiratory syncytial virus infection. J Microbiol Immunol Infect 49: 737-742. https://doi.org/10.1016/j.jmii.2014.08.020.
53. Geevarghese B, Weinberg A. 2014. Cell-mediated immune responses to respiratory syncytial virus infection: magnitude, kinetics, and correlates with morbidity and age. Hum Vaccin Immunother 10: 1047-1056. https://doi.org/10.4161/hv.27908.
54. Aberle JH, Aberle SW, Dworzak MN, Mandl CW, Rebhandl W, Vollnhofer G, Kundi M, Popow-Kraupp T. 1999. Reduced interferon-gamma expression in peripheral blood mononuclear cells of infants with severe respiratory syncytial virus disease. Am J Respir Crit Care Med 160: 1263-1268. https://doi.org/10.1164/ajrccm.160.4.9812025.
55. Bont L, Heijnen CJ, Kavelaars A, van Aalderen WM, Brus F, Draaisma JM, Pekelharing-Berghuis M, van Diemen-Steenvoorde RA, Kimpen JL. 2001. Local interferon-gamma levels during respiratory syncytial virus lower respiratory tract infection are associated with disease severity. J Infect Dis 184: 355-358. https://doi.org/10.1086/322035.
56. de Waal L, Koopman LP, van Benten IJ, Brandenburg AH, Mulder PG, de Swart RL, Fokkens WJ, Neijens HJ, Osterhaus AD. 2003. Moderate local and systemic respiratory syncytial virus-specific T-cell responses upon mild or subclinical RSV infection. J Med Virol 70: 309-318. https:// doi.org/10.1002/jmv.10396.
57. Walker M, Kublin JG, Zunt JR. 2006. Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis. Clin Infect Dis 42: 115-125. https://doi.org/10.1086/498510.
58. O’Shea DT, Humar A. 2013. Life-threatening infection in transplant recipients. Crit Care Clin 29: 953-973. https://doi.org/10.1016/j.ccc.2013.06.012.
59. Kumar D, Humar A. 2010. Respiratory viral infections in transplant and oncology patients. Infect Dis Clin North Am 24: 395-412. https:// doi.org/10.1016/j.idc.2010.01.007.
60. Traitanon O, Mathew JM, La Monica G, Xu L, Mas V, Gallon L. 2015. Differential effects of tacrolimus versus sirolimus on the proliferation, activation and differentiation of human B cells. PLoS One 10: e0129658. https://doi.org/10.1371/journal.pone.0129658.
61. Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FH, Mulder A. 2008. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 86: 1292-1300. https://doi.org/10.1097/TP.0b013e3181874a36.
62. van de Beek D, Kremers WK, Del Pozo JL, Daly RC, Edwards BS, McGregor CG, Patel R. 2008. Effect of infectious diseases on outcome after heart transplant. Mayo Clin Proc 83: 304-308. https://doi.org/10.4065/83.3.304.
63. Falsey AR, McElhaney JE, Beran J, van Essen GA, Duval X, Esen M, Galtier F, Gervais P, Hwang SJ, Kremsner P, Launay O, Leroux-Roels G, McNeil SA, Nowakowski A, Richardus JH, Ruiz-Palacios G, St Rose S, Devaster JM, Oostvogels L, Durviaux S, Taylor S. 2014. Respiratory syncytial virus and other respiratory viral infections in older adults with moderate to severe influenza-like illness. J Infect Dis 209: 1873-1881. https://doi.org/10.1093/infdis/jit839.
64. Lee N, Lui GC, Wong KT, Li TC, Tse EC, Chan JY, Yu J, Wong SS, Choi KW, Wong RY, Ngai KL, Hui DS, Chan PK. 2013. High morbidity and mortality in adults hospitalized for respiratory syncytial virus infections. Clin Infect Dis 57: 1069-1077. https://doi.org/10.1093/cid/cit471.
65. Falsey AR, Walsh EE. 1998. Relationship of serum antibody to risk of respiratory syncytial virus infection in elderly adults. J Infect Dis 177: 463-466. https://doi.org/10.1086/517376.
66. Walsh EE, Falsey AR. 2004. Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. J Infect Dis 190: 373-378. https://doi.org/10.1086/421524.
67. Frasca D, Pucci S, Goso C, Barattini P, Barile S, Pioli C, Doria G. 1997. Regulation of cytokine production in aging: use of recombinant cytokines to upregulate mitogen-stimulated spleen cells. Mech Ageing Dev 93: 157-169. https://doi.org/10.1016/S0047-6374(96)01825-8.
68. Ernst DN, Weigle WO, Noonan DJ, McQuitty DN, Hobbs MV. 1993. The age-associated increase in IFN-gamma synthesis by mouse CD8+ T cells correlates with shifts in the frequencies of cell subsets defined by membrane CD44, CD45RB, 3G11, and MEL-14 expression. J Immunol 151: 575-587.
69. Doria G, Adorini L, Sabbadini E, Mancini C, Frasca D. 1988. Immunoregulation in aging. Ann N Y Acad Sci 521: 182-188. https://doi.org/10.1111/j.1749-6632.1988.tb35277.x.
70. Malhotra R, Ward M, Bright H, Priest R, Foster MR, Hurle M, Blair E, Bird M. 2003. Isolation and characterisation of potential respiratory syncytial virus receptor(s) on epithelial cells. Microbes Infect 5: 123-133. https:// doi.org/10.1016/S1286-4579(02)00079-5.
71. Johnson SM, McNally BA, Ioannidis I, Flano E, Teng MN, Oomens AG, Walsh EE, Peeples ME. 2015. Respiratory syncytial virus uses CX3CR1 as a receptor on primary human airway epithelial cultures. PLoS Pathog 11: e1005318. https://doi.org/10.1371/journal.ppat.1005318.
72. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol 2: 732-738. https://doi.org/10.1038/90675.
73. Currier MG, Lee S, Stobart CC, Hotard AL, Villenave R, Meng J, Pretto CD, Shields MD, Nguyen MT, Todd SO, Chi MH, Hammonds J, Krumm SA, Spearman P, Plemper RK, Sakamoto K, Peebles RS, Jr, Power UF, Moore ML. 2016. EGFR interacts with the fusion protein of respiratory syncytial virus strain 2-20 and mediates infection and mucin expression. PLoS Pathog 12: e1005622. https://doi.org/10.1371/journal.ppat.1005622.
74. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol 1: 398-401. https://doi.org/10.1038/80833.
75. Marchant D, Singhera GK, Utokaparch S, Hackett TL, Boyd JH, Luo Z, Si X, Dorscheid DR, McManus BM, Hegele RG. 2010. Toll-like receptor 4-mediated activation of p38 mitogen-activated protein kinase is a determinant of respiratory virus entry and tropism. J Virol 84: 11359-11373. https://doi.org/10.1128/JVI.00804-10.
76. Behera AK, Matsuse H, Kumar M, Kong X, Lockey RF, Mohapatra SS. 2001. Blocking intercellular adhesion molecule-1 on human epithelial cells decreases respiratory syncytial virus infection. Biochem Biophys Res Commun 280: 188-195. https://doi.org/10.1006/bbrc.2000.4093.
77. Tayyari F, Marchant D, Moraes TJ, Duan W, Mastrangelo P, Hegele RG. 2011. Identification of nucleolin as a cellular receptor for human respiratory syncytial virus. Nat Med 17: 1132-1135. https://doi.org/10.1038/ nm.2444.
78. Holguera J, Villar E, Munoz-Barroso I. 2014. Identification of cellular proteins that interact with Newcastle disease virus and human respiratory syncytial virus by a two-dimensional virus overlay protein binding assay (VOPBA). Virus Res 191: 138-142. https://doi.org/10.1016/ j.virusres.2014.07.031.
79. Krusat T, Streckert HJ. 1997. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch Virol 142: 1247-1254. https://doi.org/10.1007/s007050050156.
80. Derscheid RJ, van Geelen A, McGill JL, Gallup JM, Cihlar T, Sacco RE, Ackermann MR. 2013. Human respiratory syncytial virus Memphis 37 grown in HEp-2 cells causes more severe disease in lambs than virus grown in Vero cells. Viruses 5: 2881-2897. https://doi.org/10.3390/ v5112881.
81. Rixon HW, Brown C, Brown G, Sugrue RJ. 2002. Multiple glycosylated forms of the respiratory syncytial virus fusion protein are expressed in virus-infected cells. J Gen Virol 83: 61-66. https://doi.org/10.1099/0022-1317-83-1-61.
82. Kwilas S, Liesman RM, Zhang L, Walsh E, Pickles RJ, Peeples ME. 2009. Respiratory syncytial virus grown in Vero cells contains a truncated attachment protein that alters its infectivity and dependence on gly-cosaminoglycans. J Virol 83: 10710-10718. https://doi.org/10.1128/ JVI.00986-09.
83. Zhang L, Bukreyev A, Thompson CI, Watson B, Peeples ME, Collins PL, Pickles RJ. 2005. Infection of ciliated cells by human parainfluenza virus type 3 in an in vitro model of human airway epithelium. J Virol 79: 1113-1124. https://doi.org/10.1128/JVI.79.2.1113-1124.2005.
84. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res 162: 80-99. https://doi.org/10.1016/j.virusres.2011.09.020.
85. Jeong KI, Piepenhagen PA, Kishko M, DiNapoli JM, Groppo RP, Zhang L, Almond J, Kleanthous H, Delagrave S, Parrington M. 2015. CX3CR1 is expressed in differentiated human ciliated airway cells and co-localizes with respiratory syncytial virus on cilia in a G protein-dependent manner. PLoS One 10: e0130517. https://doi.org/10.1371/journal.pone.0130517.
86. Chirkova T, Lin S, Oomens AG, Gaston KA, Boyoglu-Barnum S, Meng J, Stobart CC, Cotton CU, Hartert TV, Moore ML, Ziady AG, Anderson LJ. 2015. CX3CR1 is an important surface molecule for respiratory syncytial virus infection in human airway epithelial cells. J Gen Virol 96: 2543-2556. https://doi.org/10.1099/vir.0.000218.
87. Pfeifle J, Anderer FA. 1983. Isolation and characterization of phosphoprotein pp 105 from simian virus 40-transformed mouse fibroblasts. Biochim Biophys Acta 762: 86-93. https://doi.org/10.1016/0167-4889(83)90120-9.
88. Shakeri A, Mastrangelo P, Griffin JK, Moraes TJ, Hegele RG. 2015. Respiratory syncytial virus receptor expression in the mouse and viral tropism. Histol Histopathol 30: 401-411.
89. Fujiki H, Watanabe T, Suganuma M. 2014. Cell-surface nucleolin acts as a central mediator for carcinogenic, anti-carcinogenic, and diseaserelated ligands. J Cancer Res Clin Oncol 140: 689-699. https://doi.org/10.1007/s00432-014-1587-5.
90. Schanzer DL, Langley JM, Tam TW. 2006. Hospitalization attributable to influenza and other viral respiratory illnesses in Canadian children. Pediatr Infect Dis J 25: 795-800. https://doi.org/10.1097/01.inf.0000232632.86800.8c.
91. Thurlbeck WM. 1982. Postnatal human lung growth. Thorax 37: 564-571. https://doi.org/10.1136/thx.37.8.564.
92. Hovanessian AG, Soundaramourty C, El Khoury D, Nondier I, Svab J, Krust B. 2010. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS One 5: e15787. https://doi.org/10.1371/journal.pone.0015787.
93. Pearson WR, Wood T, Zhang Z, Miller W. 1997. Comparison of DNA sequences with protein sequences. Genomics 46: 24-36. https:// doi.org/10.1006/geno.1997.4995.
94. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340: 1113-1117. https://doi.org/10.1126/science.1234914.
95. Krzyzaniak MA, Zumstein MT, Gerez JA, Picotti P, Helenius A. 2013. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog 9: e1003309. https://doi.org/10.1371/journal.ppat.1003309.
96. San-Juan-Vergara H, Sampayo-Escobar V, Reyes N, Cha B, Pacheco-Lugo L, Wong T, Peeples ME, Collins PL, Castano ME, Mohapatra SS. 2012. Cholesterol-rich microdomains as docking platforms for respiratory syncytial virus in normal human bronchial epithelial cells. J Virol 86: 1832-1843. https://doi.org/10.1128/JVI.06274-11.
97. Hughson FM. 1995. Structural characterization of viral fusion proteins. Curr Biol 5: 265-274. https://doi.org/10.1016/S0960-9822(95)00057-1.
98. Helm CA, Israelachvili JN, McGuiggan PM. 1989. Molecular mechanisms and forces involved in the adhesion and fusion of amphiphilic bilayers. Science 246: 919-922. https://doi.org/10.1126/science.2814514.
99. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342: 592-598. https://doi.org/10.1126/science.1243283.
100. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85: 7788-7796. https://doi.org/10.1128/JVI.00555-11.
101. Noton SL, Nagendra K, Dunn EF, Mawhorter ME, Yu Q, Fearns R. 2015. Respiratory syncytial virus inhibitor AZ-27 differentially inhibits different polymerase activities at the promoter. J Virol 89: 7786-7798. https://doi.org/10.1128/JVI.00530-15.
102. DeVincenzo JP, McClure MW, Symons JA, Fathi H, Westland C, Chanda S, Lambkin-Williams R, Smith P, Zhang Q, Beigelman L, Blatt LM, Fry J. 2015. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 373: 2048-2058. https://doi.org/10.1056/ NEJMoa1413275.
103. McDonald TP, Pitt AR, Brown G, Rixon HW, Sugrue RJ. 2004. Evidence that the respiratory syncytial virus polymerase complex associates with lipid rafts in virus-infected cells: a proteomic analysis. Virology 330: 147-157. https://doi.org/10.1016/j.virol.2004.09.034.
104. Munday DC, Wu W, Smith N, Fix J, Noton SL, Galloux M, Touzelet O, Armstrong SD, Dawson JM, Aljabr W, Easton AJ, Rameix-Welti MA, de Oliveira AP, Simabuco FM, Ventura AM, Hughes DJ, Barr JN, Fearns R, Digard P, Eleouet JF, Hiscox JA. 2015. Interactome analysis of the human respiratory syncytial virus RNA polymerase complex identifies protein chaperones as important cofactors that promote L-protein stability and RNA synthesis. J Virol 89: 917-930. https://doi.org/10.1128/ JVI.01783-14.
105. Radhakrishnan A, Yeo D, Brown G, Myaing MZ, Iyer LR, Fleck R, Tan BH, Aitken J, Sanmun D, Tang K, Yarwood A, Brink J, Sugrue RJ. 2010. Protein analysis of purified respiratory syncytial virus particles reveals an important role for heat shock protein 90 in virus particle assembly. Mol Cell Proteomics 9: 1829-1848. https://doi.org/10.1074/mcp.M110.001651.
106. Boyer JC, Haenni AL. 1994. Infectious transcripts and cDNA clones of RNA viruses. Virology 198: 415-426. https://doi.org/10.1006/viro.1994.1053.
107. Fearns R, Peeples ME, Collins PL. 2002. Mapping the transcription and replication promoters of respiratory syncytial virus. J Virol 76: 1663-1672. https://doi.org/10.1128/JVI.76.4.1663-1672.2002.
108. McGivern DR, Collins PL, Fearns R. 2005. Identification of internal sequences in the 3= leader region of human respiratory syncytial virus that enhance transcription and confer replication processivity. J Virol 79: 2449-2460. https://doi.org/10.1128/JVI.79.4.2449-2460.2005.
109. Hanley LL, McGivern DR, Teng MN, Djang R, Collins PL, Fearns R. 2010. Roles of the respiratory syncytial virus trailer region: effects of mutations on genome production and stress granule formation. Virology 406: 241-252. https://doi.org/10.1016/j.virol.2010.07.006.
110. Fearns R, Collins PL, Peeples ME. 2000. Functional analysis of the genomic and antigenomic promoters of human respiratory syncytial virus. J Virol 74: 6006-6014. https://doi.org/10.1128/JVI.74.13.6006-6014.2000.
111. Dickens LE, Collins PL, Wertz GW. 1984. Transcriptional mapping of human respiratory syncytial virus. J Virol 52: 364-369.
112. Kuo L, Grosfeld H, Cristina J, Hill MG, Collins PL. 1996. Effects of mutations in the gene-start and gene-end sequence motifs on transcription of monocistronic and dicistronic minigenomes of respiratory syncytial virus. J Virol 70: 6892-6901.
113. Bermingham A, Collins PL. 1999. The M2-2 protein of human respiratory syncytial virus is a regulatory factor involved in the balance between RNA replication and transcription. Proc Natl Acad Sci U S A 96: 11259-11264. https://doi.org/10.1073/pnas.96.20.11259.
114. Cowton VM, Fearns R. 2005. Evidence that the respiratory syncytial virus polymerase is recruited to nucleotides 1 to 11 at the 3= end of the nucleocapsid and can scan to access internal signals. J Virol 79: 11311-11322. https://doi.org/10.1128/JVI.79.17.11311-11322.2005.
115. Noton SL, Cowton VM, Zack CR, McGivern DR, Fearns R. 2010. Evidence that the polymerase of respiratory syncytial virus initiates RNA replication in a nontemplated fashion. Proc Natl Acad Sci U S A 107: 10226-10231. https://doi.org/10.1073/pnas.0913065107.
116. Noton SL, Fearns R. 2011. The first two nucleotides of the respiratory syncytial virus antigenome RNA replication product can be selected independently of the promoter terminus. RNA 17: 1895-1906. https:// doi.org/10.1261/rna.2813411.
117. Noton SL, Deflube LR, Tremaglio CZ, Fearns R. 2012. The respiratory syncytial virus polymerase has multiple RNA synthesis activities at the promoter. PLoS Pathog 8: e1002980. https://doi.org/10.1371/ journal.ppat.1002980.
118. Tremaglio CZ, Noton SL, Deflube LR, Fearns R. 2013. Respiratory syncytial virus polymerase can initiate transcription from position 3 of the leader promoter. J Virol 87: 3196-3207. https://doi.org/10.1128/ JVI.02862-12.
119. Noton SL, Aljabr W, Hiscox JA, Matthews DA, Fearns R. 2014. Factors affecting de novo RNA synthesis and back-priming by the respiratory syncytial virus polymerase. Virology 462-463: 318-327. https://doi.org/10.1016/j.virol.2014.05.032.
120. Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L, Castagne N, MacLellan K, Bedouelle H, Bricogne G, Bhella D, Eleouet JF, Rey FA. 2009. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 326: 1279-1283. https:// doi.org/10.1126/science.1177634.
121. Santangelo PJ, Lifland AW, Curt P, Sasaki Y, Bassell GJ, Lindquist ME, Crowe JE, Jr. 2009. Single molecule-sensitive probes for imaging RNA in live cells. Nat Methods 6: 347-349. https://doi.org/10.1038/nmeth.1316.
122. Samal SK, Collins PL. 1996. RNA replication by a respiratory syncytial virus RNA analog does not obey the rule of six and retains a nonviral trinucleotide extension at the leader end. J Virol 70: 5075-5082.
123. Norrby E, Marusyk H, Orvell C. 1970. Morphogenesis of respiratory syncytial virus in a green monkey kidney cell line (Vero). J Virol 6: 237-242.
124. Lifland AW, Jung J, Alonas E, Zurla C, Crowe JE, Jr, Santangelo PJ. 2012. Human respiratory syncytial virus nucleoprotein and inclusion bodies antagonize the innate immune response mediated by MDA5 and MAVS. J Virol 86: 8245-8258. https://doi.org/10.1128/JVI.00215-12.
125. Carromeu C, Simabuco FM, Tamura RE, Farinha Arcieri LE, Ventura AM. 2007. Intracellular localization of human respiratory syncytial virus L protein. Arch Virol 152: 2259-2263. https://doi.org/10.1007/s00705-007-1048-4.
126. Garcia J, Garcia-Barreno B, Vivo A, Melero JA. 1993. Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein. Virology 195: 243-247. https://doi.org/10.1006/viro.1993.1366.
127. Lindquist ME, Lifland AW, Utley TJ, Santangelo PJ, Crowe JE, Jr. 2010. Respiratory syncytial virus induces host RNA stress granules to facilitate viral replication. J Virol 84: 12274-12284. https://doi.org/10.1128/ JVI.00260-10.
128. Fricke J, Koo LY, Brown CR, Collins PL. 2013. p38 and OGT sequestration into viral inclusion bodies in cells infected with human respiratory syncytial virus suppresses MK2 activities and stress granule assembly. J Virol 87: 1333-1347. https://doi.org/10.1128/JVI.02263-12.
129. Brown G, Rixon HW, Steel J, McDonald TP, Pitt AR, Graham S, Sugrue RJ. 2005. Evidence for an association between heat shock protein 70 and the respiratory syncytial virus polymerase complex within lipid-raft membranes during virus infection. Virology 338: 69-80. https://doi.org/10.1016/j.virol.2005.05.004.
130. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, Martinez-Sobrido L, Akira S, Gill MA, Garcia-Sastre A, Katze MG, Gale M, Jr. 2008. Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 82: 335-345. https://doi.org/10.1128/JVI.01080-07.
131. Ohn T, Kedersha N, Hickman T, Tisdale S, Anderson P. 2008. A functional RNAi screen links O-GlcNAc modification of ribosomal proteins to stress granule and processing body assembly. Nat Cell Biol 10: 1224-1231. https://doi.org/10.1038/ncb1783.
132. Lindquist ME, Mainou BA, Dermody TS, Crowe JE, Jr. 2011. Activation of protein kinase R is required for induction of stress granules by respiratory syncytial virus but dispensable for viral replication. Virology 413: 103-110. https://doi.org/10.1016/j.virol.2011.02.009.
133. Groskreutz DJ, Babor EC, Monick MM, Varga SM, Hunninghake GW. 2010. Respiratory syncytial virus limits alpha subunit of eukaryotic translation initiation factor 2 (eIF2alpha) phosphorylation to maintain translation and viral replication. J Biol Chem 285: 24023-24031. https:// doi.org/10.1074/jbc.M109.077321.
134. Onomoto K, Yoneyama M, Fung G, Kato H, Fujita T. 2014. Antiviral innate immunity and stress granule responses. Trends Immunol 35: 420-428. https://doi.org/10.1016/j.it.2014.07.006.
135. Montero H, Trujillo-Alonso V. 2011. Stress granules in the viral replication cycle. Viruses 3: 2328-2338. https://doi.org/10.3390/v3112328.
136. Iseni F, Garcin D, Nishio M, Kedersha N, Anderson P, Kolakofsky D. 2002. Sendai virus trailer RNA binds TIAR, a cellular protein involved in virus-induced apoptosis. EMBO J 21: 5141-5150. https://doi.org/10.1093/emboj/cdf513.
137. Kim SR, Kim DI, Kang MR, Lee KS, Park SY, Jeong JS, Lee YC. 2013. Endoplasmic reticulum stress influences bronchial asthma pathogenesis by modulating nuclear factor kappaB activation. J Allergy Clin Immunol 132: 1397-1408. https://doi.org/10.1016/j.jaci.2013.08.041.
138. Utokaparch S, Marchant D, Gosselink JV, McDonough JE, Thomas EE, Hogg JC, Hegele RG. 2011. The relationship between respiratory viral loads and diagnosis in children presenting to a pediatric hospital emergency department. Pediatr Infect Dis J 30: e18-e23. https:// doi.org/10.1097/INF.0b013e3181ff2fac.
139. DeVincenzo JP, Wilkinson T, Vaishnaw A, Cehelsky J, Meyers R, Nochur S, Harrison L, Meeking P, Mann A, Moane E, Oxford J, Pareek R, Moore R, Walsh E, Studholme R, Dorsett P, Alvarez R, Lambkin-Williams R. 2010. Viral load drives disease in humans experimentally infected with respiratory syncytial virus. Am J Respir Crit Care Med 182: 1305-1314. https://doi.org/10.1164/rccm.201002-0221OC.
140. McNamara PS, Ritson P, Selby A, Hart CA, Smyth RL. 2003. Bronchoalveolar lavage cellularity in infants with severe respiratory syncytial virus bronchiolitis. Arch Dis Child 88: 922-926. https://doi.org/10.1136/ adc.88.10.922.
141. Everard ML, Swarbrick A, Wrightham M, McIntyre J, Dunkley C, James PD, Sewell HF, Milner AD. 1994. Analysis of cells obtained by bronchial lavage of infants with respiratory syncytial virus infection. Arch Dis Child 71: 428-432. https://doi.org/10.1136/adc.71.5.428.
142. Hussell T, Openshaw PJ. 1998. Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. J Gen Virol 79: 2593-2601. https:// doi.org/10.1099/0022-1317-79-11-2593.
143. Anderson JJ, Norden J, Saunders D, Toms GL, Scott R. 1990. Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection. J Gen Virol 71: 1561-1570. https://doi.org/10.1099/0022-1317-71-7-1561.
144. Welliver TP, Reed JL, Welliver RC, Sr. 2008. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J 27: S92-S96. https://doi.org/10.1097/ INF.0b013e318168b706.
145. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Suffin SC, Cohen HJ. 1986. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med 315: 77-81. https:// doi.org/10.1056/NEJM198607103150201.
146. McIntosh K, Masters HB, Orr I, Chao RK, Barkin RM. 1978. The immunologic response to infection with respiratory syncytial virus in infants. J Infect Dis 138: 24-32. https://doi.org/10.1093/infdis/138.1.24.
147. Johnson TR, Graham BS. 1999. Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol 73: 8485-8495.
148. Bembridge GP, Garcia-Beato R, Lopez JA, Melero JA, Taylor G. 1998. Subcellular site of expression and route of vaccination influence pulmonary eosinophilia following respiratory syncytial virus challenge in BALB/c mice sensitized to the attachment G protein. J Immunol 161: 2473-2480.
149. Johnson TR, Johnson JE, Roberts SR, Wertz GW, Parker RA, Graham BS. 1998. Priming with secreted glycoprotein G of respiratory syncytial virus (RSV) augments interleukin-5 production and tissue eosinophilia after RSV challenge. J Virol 72: 2871-2880.
150. Sparer TE, Matthews S, Hussell T, Rae AJ, Garcia-Barreno B, Melero JA, Openshaw PJ. 1998. Eliminating a region of respiratory syncytial virus attachment protein allows induction of protective immunity without vaccine-enhanced lung eosinophilia. J Exp Med 187: 1921-1926. https:// doi.org/10.1084/jem.187.11.1921.
151. Tebbey PW, Hagen M, Hancock GE. 1998. Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus. J Exp Med 188: 1967-1972. https://doi.org/10.1084/jem.188.10.1967.
152. Scott KA, Wardlaw AJ. 2006. Eosinophilic airway disorders. Semin Respir Crit Care Med 27: 128-133. https://doi.org/10.1055/s-2006-939515.
153. Prince GA, Curtis SJ, Yim KC, Porter DD. 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82: 2881-2888. https://doi.org/10.1099/0022-1317-82-12-2881.
154. Knudson CJ, Hartwig SM, Meyerholz DK, Varga SM. 2015. RSV vaccineenhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets. PLoS Pathog 11: e1004757. https://doi.org/10.1371/ journal.ppat.1004757.
155. Wright C, Oliver KC, Fenwick FI, Smith NM, Toms GL. 1997. A monoclonal antibody pool for routine immunohistochemical detection of human respiratory syncytial virus antigens in formalin-fixed, paraffin-embedded tissue. J Pathol 182: 238-244. https://doi.org/10.1002/(SICI)1096-9896(199706)182: 2<238:: AID-PATH822>3.0.CO;2-7.
156. Levenson RM, Kantor OS. 1987. Fatal pneumonia in an adult due to respiratory syncytial virus. Arch Intern Med 147: 791-792.
157. Neilson KA, Yunis EJ. 1990. Demonstration of respiratory syncytial virus in an autopsy series. Pediatr Pathol 10: 491-502. https://doi.org/10.3109/15513819009067138.
158. Delage G, Brochu P, Robillard L, Jasmin G, Joncas JH, Lapointe N. 1984. Giant cell pneumonia due to respiratory syncytial virus. Occurrence in severe combined immunodeficiency syndrome. Arch Pathol Lab Med 108: 623-625.
159. Zhang L, Peeples ME, Boucher RC, Collins PL, Pickles RJ. 2002. Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol 76: 5654-5666. https://doi.org/10.1128/JVI.76.11.5654-5666.2002.
160. Bagga B, Woods CW, Veldman TH, Gilbert A, Mann A, Balaratnam G, Lambkin-Williams R, Oxford JS, McClain MT, Wilkinson T, Nicholson BP, Ginsburg GS, Devincenzo JP. 2013. Comparing influenza and RSV viral and disease dynamics in experimentally infected adults predicts clinical effectiveness of RSV antivirals. Antivir Ther 18: 785-791. https://doi.org/10.3851/IMP2629.
161. El Saleeby CM, Bush AJ, Harrison LM, Aitken JA, Devincenzo JP. 2011. Respiratory syncytial virus load, viral dynamics, and disease severity in previously healthy naturally infected children. J Infect Dis 204: 996-1002. https://doi.org/10.1093/infdis/jir494.
162. Liesman RM, Buchholz UJ, Luongo CL, Yang L, Proia AD, DeVincenzo JP, Collins PL, Pickles RJ. 2014. RSV-encoded NS2 promotes epithelial cell shedding and distal airway obstruction. J Clin Invest 124: 2219-2233. https://doi.org/10.1172/JCI72948.
163. Simoes EA, Hayward AR, Ponnuraj EM, Straumanis JP, Stenmark KR, Wilson HL, Babu PG. 1999. Respiratory syncytial virus infects the bonnet monkey, Macaca radiata. Pediatr Dev Pathol 2: 316-326. https://doi.org/10.1007/s100249900129.
164. Aherne W, Bird T, Court SD, Gardner PS, McQuillin J. 1970. Pathological changes in virus infections of the lower respiratory tract in children. J Clin Pathol 23: 7-18. https://doi.org/10.1136/jcp.23.1.7.
165. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. 2007. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20: 108-119. https://doi.org/10.1038/ modpathol.3800725.
166. Stokes KL, Currier MG, Sakamoto K, Lee S, Collins PL, Plemper RK, Moore ML. 2013. The respiratory syncytial virus fusion protein and neutrophils mediate the airway mucin response to pathogenic respiratory syncytial virus infection. J Virol 87: 10070-10082. https://doi.org/10.1128/ JVI.01347-13.
167. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, Weinrauch Y, Zychlinsky A. 2004. Neutrophil extracellular traps kill bacteria. Science 303: 1532-1535. https://doi.org/10.1126/science.1092385.
168. Cortjens B, de Boer OJ, de Jong R, Antonis AF, Sabogal Pineros YS, Lutter R, van Woensel JB, Bem RA. 2016. Neutrophil extracellular traps cause airway obstruction during respiratory syncytial virus disease. J Pathol 238: 401-411. https://doi.org/10.1002/path.4660.
169. Funchal GA, Jaeger N, Czepielewski RS, Machado MS, Muraro SP, Stein RT, Bonorino CB, Porto BN. 2015. Respiratory syncytial virus fusion protein promotes TLR-4-dependent neutrophil extracellular trap formation by human neutrophils. PLoS One 10: e0124082. https://doi.org/10.1371/journal.pone.0124082.
170. Tang FS, Van Ly D, Spann K, Reading PC, Burgess JK, Hartl D, Baines KJ, Oliver BG. 2016. Differential neutrophil activation in viral infections: enhanced TLR-7/8-mediated CXCL8 release in asthma. Respirology 21: 172-179. https://doi.org/10.1111/resp.12657.
171. Geerdink RJ, Pillay J, Meyaard L, Bont L. 2015. Neutrophils in respiratory syncytial virus infection: a target for asthma prevention. J Allergy Clin Immunol 136: 838-847. https://doi.org/10.1016/j.jaci.2015.06.034.
172. Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P. 2016. The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma. Ther Adv Respir Dis 10: 158-174. https:// doi.org/10.1177/1753465815618113.
173. Seemungal TA, Wedzicha JA. 2003. Viral infections in obstructive airway diseases. Curr Opin Pulm Med 9: 111-116. https://doi.org/10.1097/00063198-200303000-00004.
174. Patel DA, You Y, Huang G, Byers DE, Kim HJ, Agapov E, Moore ML, Peebles RS, Jr, Castro M, Sumino K, Shifren A, Brody SL, Holtzman MJ. 2014. Interferon response and respiratory virus control are preserved in bronchial epithelial cells in asthma. J Allergy Clin Immunol 134: 1402-1412. https://doi.org/10.1016/j.jaci.2014.07.013.
175. Spann KM, Baturcam E, Schagen J, Jones C, Straub CP, Preston FM, Chen L, Phipps S, Sly PD, Fantino E. 2014. Viral and host factors determine innate immune responses in airway epithelial cells from children with wheeze and atopy. Thorax 69: 918-925. https://doi.org/10.1136/thoraxjnl-2013-204908.
176. Tighe RM, Li Z, Potts EN, Frush S, Liu N, Gunn MD, Foster WM, Noble PW, Hollingsworth JW. 2011. Ozone inhalation promotes CX3CR1-dependent maturation of resident lung macrophages that limit oxidative stress and inflammation. J Immunol 187: 4800-4808. https:// doi.org/10.4049/jimmunol.1101312.
177. Hammad H, Chieppa M, Perros F, Willart MA, Germain RN, Lambrecht BN. 2009. House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells. Nat Med 15: 410-416. https:// doi.org/10.1038/nm.1946.
178. Carroll KN, Wu P, Gebretsadik T, Griffin MR, Dupont WD, Mitchel EF, Hartert TV. 2009. Season of infant bronchiolitis and estimates of subsequent risk and burden of early childhood asthma. J Allergy Clin Immunol 123: 964-966. https://doi.org/10.1016/j.jaci.2008.12.011.
179. Sigurs N, Aljassim F, Kjellman B, Robinson PD, Sigurbergsson F, Bjarnason R, Gustafsson PM. 2010. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 65: 1045-1052. https://doi.org/10.1136/thx.2009.121582.
180. You D, Becnel D, Wang K, Ripple M, Daly M, Cormier SA. 2006. Exposure of neonates to respiratory syncytial virus is critical in determining subsequent airway response in adults. Respir Res 7: 107. https://doi.org/10.1186/1465-9921-7-107.
181. Blanken MO, Rovers MM, Molenaar JM, Winkler-Seinstra PL, Meijer A, Kimpen JL, Bont L, Dutch RSV Neonatal Network. 2013. Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. N Engl J Med 368: 1791-1799. https://doi.org/10.1056/NEJMoa1211917.
182. Wills-Karp M. 2004. Interleukin-13 in asthma pathogenesis. Immunol Rev 202: 175-190. https://doi.org/10.1111/j.0105-2896.2004.00215.x.
183. Saravia J, You D, Shrestha B, Jaligama S, Siefker D, Lee GI, Harding JN, Jones TL, Rovnaghi C, Bagga B, DeVincenzo JP, Cormier SA. 2015. Respiratory syncytial virus disease is mediated by age-variable IL-33. PLoS Pathog 11: e1005217. https://doi.org/10.1371/journal.ppat.1005217.
184. Tanaka S, Motomura Y, Suzuki Y, Yagi R, Inoue H, Miyatake S, Kubo M. 2011. The enhancer HS2 critically regulates GATA-3-mediated Il4 transcription in T(H)2 cells. Nat Immunol 12: 77-85. https://doi.org/10.1038/ ni.1966.
185. Wadsworth SJ, Atsuta R, McIntyre JO, Hackett TL, Singhera GK, Dorscheid DR. 2010. IL-13 and TH2 cytokine exposure triggers matrix metalloproteinase 7-mediated Fas ligand cleavage from bronchial epithelial cells. J Allergy Clin Immunol 126: 366-374. https://doi.org/10.1016/ j.jaci.2010.05.015.
186. Xu J, Singhera GK, Dorscheid DR. 2015. Expression of surfactant protein D in airways of asthmatics and interleukin-13 modulation of surfactant protein D in human models of airway epithelium. Respir Res 16: 26. https://doi.org/10.1186/s12931-015-0177-7.
187. Peters MC, Mekonnen ZK, Yuan S, Bhakta NR, Woodruff PG, Fahy JV. 2014. Measures of gene expression in sputum cells can identify TH2-high and TH2-low subtypes of asthma. J Allergy Clin Immunol 133: 388-394. https://doi.org/10.1016/j.jaci.2013.07.036.
188. Chung KF. 2015. Targeting the interleukin pathway in the treatment of asthma. Lancet 386: 1086-1096. https://doi.org/10.1016/S0140-6736(15)00157-9.
189. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, Bucks C, Kane CM, Fallon PG, Pannell R, Jolin HE, McKenzie AN. 2010. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature 464: 1367-1370. https://doi.org/10.1038/nature08900.
190. Damasio GA, Pereira LA, Moreira SD, Duarte dos Santos CN, Dalla-Costa LM, Raboni SM. 2015. Does virus-bacteria coinfection increase the clinical severity of acute respiratory infection? J Med Virol 87: 1456-1461. https://doi.org/10.1002/jmv.24210.
191. Jiang W, Wang T, Li L, Ji W, Wang Y, Yan Y. 2016. Impact of bacteria in nasal aspirates on disease severity of bronchiolitis. Infect Dis (Lond) 48: 82-86. https://doi.org/10.3109/23744235.2015.1082621.
192. Korppi M, Leinonen M, Koskela M, Makela PH, Launiala K. 1989. Bacterial coinfection in children hospitalized with respiratory syncytial virus infections. Pediatr Infect Dis J 8: 687-692. https://doi.org/10.1097/00006454-198910000-00005.
193. Randolph AG, Reder L, Englund JA. 2004. Risk of bacterial infection in previously healthy respiratory syncytial virus-infected young children admitted to the intensive care unit. Pediatr Infect Dis J 23: 990-994. https://doi.org/10.1097/01.inf.0000143647.88873.66.
194. Thorburn K, Harigopal S, Reddy V, Taylor N, van Saene HK. 2006. High incidence of pulmonary bacterial co-infection in children with severe respiratory syncytial virus (RSV) bronchiolitis. Thorax 61: 611-615. https://doi.org/10.1136/thx.2005.048397.
195. Duttweiler L, Nadal D, Frey B. 2004. Pulmonary and systemic bacterial co-infections in severe RSV bronchiolitis. Arch Dis Child 89: 1155-1157. https://doi.org/10.1136/adc.2004.049551.
196. Suarez-Arrabal MC, Mella C, Lopez SM, Brown NV, Hall MW, Hammond S, Shiels W, Groner J, Marcon M, Ramilo O, Mejias A. 2015. Nasopharyngeal bacterial burden and antibiotics: influence on inflammatory markers and disease severity in infants with respiratory syncytial virus bronchiolitis. J Infect 71: 458-469. https://doi.org/10.1016/ j.jinf.2015.06.010.
197. Caballero MT, Serra ME, Acosta PL, Marzec J, Gibbons L, Salim M, Rodriguez A, Reynaldi A, Garcia A, Bado D, Buchholz UJ, Hijano DR, Coviello S, Newcomb D, Bellabarba M, Ferolla FM, Libster R, Berenstein A, Siniawaski S, Blumetti V, Echavarria M, Pinto L, Lawrence A, Ossorio MF, Grosman A, Mateu CG, Bayle C, Dericco A, Pellegrini M, Igarza I, Repetto HA, Grimaldi LA, Gudapati P, Polack NR, Althabe F, Shi M, Ferrero F, Bergel E, Stein RT, Peebles RS, Boothby M, Kleeberger SR, Polack FP. 2015. TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization. J Clin Invest 125: 571-582. https://doi.org/10.1172/JCI75183.
198. Friis B, Andersen P, Brenoe E, Hornsleth A, Jensen A, Knudsen FU, Krasilnikoff PA, Mordhorst CH, Nielsen S, Uldall P. 1984. Antibiotic treatment of pneumonia and bronchiolitis. A prospective randomised study. Arch Dis Child 59: 1038-1045.
199. Field CM, Connolly JH, Murtagh G, Slattery CM, Turkington EE. 1966. Antibiotic treatment of epidemic bronchiolitis-a double-blind trial. Br Med J 1: 83-85. https://doi.org/10.1136/bmj.1.5479.83.
200. Nguyen DT, Louwen R, Elberse K, van Amerongen G, Yuksel S, Luijendijk A, Osterhaus AD, Duprex WP, de Swart RL. 2015. Streptococcus pneumoniae enhances human respiratory syncytial virus infection in vitro and in vivo. PLoS One 10: e0127098. https://doi.org/10.1371/ journal.pone.0127098.
201. Gulraiz F, Bellinghausen C, Bruggeman CA, Stassen FR. 2015. Haemophilus influenzae increases the susceptibility and inflammatory response of airway epithelial cells to viral infections. FASEB J 29: 849-858. https://doi.org/10.1096/fj.14-254359.
202. Madhi SA, Klugman KP, Vaccine Trialist Group. 2004. A role for Streptococcus pneumoniae in virus-associated pneumonia. Nat Med 10: 811-813. https://doi.org/10.1038/nm1077.
203. Hament JM, Aerts PC, Fleer A, Van Dijk H, Harmsen T, Kimpen JL, Wolfs TF. 2004. Enhanced adherence of Streptococcus pneumoniae to human epithelial cells infected with respiratory syncytial virus. Pediatr Res 55: 972-978. https://doi.org/10.1203/01.PDR.0000127431.11750.D9.
204. Ishizuka S, Yamaya M, Suzuki T, Takahashi H, Ida S, Sasaki T, Inoue D, Sekizawa K, Nishimura H, Sasaki H. 2003. Effects of rhinovirus infection on the adherence of Streptococcus pneumoniae to cultured human airway epithelial cells. J Infect Dis 188: 1928-1939. https://doi.org/10.1086/379833.
205. Jiang Z, Nagata N, Molina E, Bakaletz LO, Hawkins H, Patel JA. 1999. Fimbria-mediated enhanced attachment of nontypeable Haemophilus influenzae to respiratory syncytial virus-infected respiratory epithelial cells. Infect Immun 67: 187-192.
206. Avadhanula V, Rodriguez CA, Devincenzo JP, Wang Y, Webby RJ, Ulett GC, Adderson EE. 2006. Respiratory viruses augment the adhesion of bacterial pathogens to respiratory epithelium in a viral species-and cell type-dependent manner. J Virol 80: 1629-1636. https://doi.org/10.1128/JVI.80.4.1629-1636.2006.
207. Smith CM, Sandrini S, Datta S, Freestone P, Shafeeq S, Radhakrishnan P, Williams G, Glenn SM, Kuipers OP, Hirst RA, Easton AJ, Andrew PW, O’Callaghan C. 2014. Respiratory syncytial virus increases the virulence of Streptococcus pneumoniae by binding to penicillin binding protein 1a. A new paradigm in respiratory infection. Am J Respir Crit Care Med 190: 196-207. https://doi.org/10.1164/rccm.201311-2110OC.
208. Avadhanula V, Wang Y, Portner A, Adderson E. 2007. Nontypeable Haemophilus influenzae and Streptococcus pneumoniae bind respiratory syncytial virus glycoprotein. J Med Microbiol 56: 1133-1137. https://doi.org/10.1099/jmm.0.47086-0.
209. Hament JM, Aerts PC, Fleer A, van Dijk H, Harmsen T, Kimpen JL, Wolfs TF. 2005. Direct binding of respiratory syncytial virus to pneumococci: a phenomenon that enhances both pneumococcal adherence to human epithelial cells and pneumococcal invasiveness in a murine model. Pediatr Res 58: 1198-1203. https://doi.org/10.1203/01.pdr.0000188699.55279.1b.
210. Feikin DR, Njenga MK, Bigogo G, Aura B, Gikunju S, Balish A, Katz MA, Erdman D, Breiman RF. 2013. Additional diagnostic yield of adding serology to PCR in diagnosing viral acute respiratory infections in Kenyan patients 5 years of age and older. Clin Vaccine Immunol 20: 113-114. https://doi.org/10.1128/CVI.00325-12.
211. Falsey AR, Formica MA, Walsh EE. 2002. Diagnosis of respiratory syncytial virus infection: comparison of reverse transcription-PCR to viral culture and serology in adults with respiratory illness. J Clin Microbiol 40: 817-820. https://doi.org/10.1128/JCM.40.3.817-820.2002.
212. Murata Y, Falsey AR. 2007. Respiratory syncytial virus infection in adults. Antivir Ther 12: 659-670.
213. Mazur NI, Martinon-Torres F, Baraldi E, Fauroux B, Greenough A, Heikkinen T, Manzoni P, Mejias A, Nair H, Papadopoulos NG, Polack FP, Ramilo O, Sharland M, Stein R, Madhi SA, Bont L, Respiratory Syncytial Virus Network (ReSViNET). 2015. Lower respiratory tract infection caused by respiratory syncytial virus: current management and new therapeutics. Lancet Respir Med 3: 888-900. https://doi.org/10.1016/ S2213-2600(15)00255-6.
214. van Remmerden Y, Xu F, van Eldik M, Heldens JG, Huisman W, Widjojoatmodjo MN. 2012. An improved respiratory syncytial virus neutralization assay based on the detection of green fluorescent protein expression and automated plaque counting. Virol J 9: 253. https:// doi.org/10.1186/1743-422X-9-253.
215. Zambon M. 1999. Active and passive immunisation against respiratory syncytial virus. Rev Med Virol 9: 227-236. https://doi.org/10.1002/(SICI)1099-1654(199910/12)9: 4<227:: AID-RMV251>3.0.CO;2-K.
216. Piedra PA, Jewell AM, Cron SG, Atmar RL, Glezen WP. 2003. Correlates of immunity to respiratory syncytial virus (RSV) associatedhospitalization: establishment of minimum protective threshold levels of serum neutralizing antibodies. Vaccine 21: 3479-3482. https:// doi.org/10.1016/S0264-410X(03)00355-4.
217. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, Yassine HM, Moin SM, Killikelly AM, Chuang GY, Druz A, Georgiev IS, Rundlet EJ, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Nason MC, Capella C, Peeples ME, Ledgerwood JE, McLellan JS, Kwong PD, Graham BS. 2015. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7: 309ra162. https://doi.org/10.1126/scitranslmed.aac4241.
218. Arbiza J, Taylor G, Lopez JA, Furze J, Wyld S, Whyte P, Stott EJ, Wertz G, Sullender W, Trudel M, Melero JA. 1992. Characterization of two antigenic sites recognized by neutralizing monoclonal antibodies directed against the fusion glycoprotein of human respiratory syncytial virus. J Gen Virol 73: 2225-2234. https://doi.org/10.1099/0022-1317-73-9-2225.
219. Beeler JA, van Wyke Coelingh K. 1989. Neutralization epitopes of the F glycoprotein of respiratory syncytial virus: effect of mutation upon fusion function. J Virol 63: 2941-2950.
220. Krarup A, Truan D, Furmanova-Hollenstein P, Bogaert L, Bouchier P, Bisschop IJ, Widjojoatmodjo MN, Zahn R, Schuitemaker H, McLellan JS, Langedijk JP. 2015. A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism. Nat Commun 6: 8143. https://doi.org/10.1038/ncomms9143.
221. Shinoff JJ, O’Brien KL, Thumar B, Shaw JB, Reid R, Hua W, Santosham M, Karron RA. 2008. Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus. J Infect Dis 198: 1007-1015. https://doi.org/10.1086/591460.
222. Hall CB, Walsh EE, Long CE, Schnabel KC. 1991. Immunity to and frequency of reinfection with respiratory syncytial virus. J Infect Dis 163: 693-698. https://doi.org/10.1093/infdis/163.4.693.
223. Habibi MS, Jozwik A, Makris S, Dunning J, Paras A, DeVincenzo JP, de Haan CA, Wrammert J, Openshaw PJ, Chiu C, Mechanisms of Severe Acute Influenza Consortium Investigators. 2015. Impaired antibodymediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am J Respir Crit Care Med 191: 1040-1049. https://doi.org/10.1164/rccm.201412-2256OC.
224. Renegar KB, Small PA, Jr, Boykins LG, Wright PF. 2004. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173: 1978-1986. https://doi.org/10.4049/ jimmunol.173.3.1978.
225. Renegar KB, Johnson CD, Dewitt RC, King BK, Li J, Fukatsu K, Kudsk KA. 2001. Impairment of mucosal immunity by total parenteral nutrition: requirement for IgA in murine nasotracheal anti-influenza immunity. J Immunol 166: 819-825. https://doi.org/10.4049/jimmunol.166.2.819.
226. Glenn GM, Fries LF, Thomas DN, Smith G, Kpamegan E, Lu H, Flyer D, Jani D, Hickman SP, Piedra PA. 2016. A randomized, blinded, controlled, dose-ranging study of a respiratory syncytial virus recombinant fusion (F) nanoparticle vaccine in healthy women of childbearing age. J Infect Dis 213: 411-422. https://doi.org/10.1093/infdis/jiv406.
227. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. 2012. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 31: 5-9. https://doi.org/10.1097/INF.0b013e31822e68e6.
228. Yang L, Chan KH, Suen LK, Chan KP, Wang X, Cao P, He D, Peiris JS, Wong CM. 2015. Age-specific epidemic waves of influenza and respiratory syncytial virus in a subtropical city. Sci Rep 5: 10390. https:// doi.org/10.1038/srep10390.
229. Paynter S. 2015. Humidity and respiratory virus transmission in tropical and temperate settings. Epidemiol Infect 143: 1110-1118. https:// doi.org/10.1017/S0950268814002702.
230. Department of Health. 11 October 2016. Australian influenza surveillance report and activity updates. Department of Health, Australian Government, Canberra, Australia. http://www.health.gov.au/flureport.
231. Haynes AK, Prill MM, Iwane MK, Gerber SI, Centers for Disease Control and Prevention (CDC). 2014. Respiratory syncytial virus-United States, July 2012-June 2014. MMWR Morb Mortal Wkly Rep 63: 1133-1136.
232. Bloom-Feshbach K, Alonso WJ, Charu V, Tamerius J, Simonsen L, Miller MA, Viboud C. 2013. Latitudinal variations in seasonal activity of influenza and respiratory syncytial virus (RSV): a global comparative review. PLoS One 8: e54445. https://doi.org/10.1371/journal.pone.0054445.
233. Agoti CN, Otieno JR, Ngama M, Mwihuri AG, Medley GF, Cane PA, Nokes DJ. 2015. Successive respiratory syncytial virus epidemics in local populations arise from multiple variant introductions providing insights into virus persistence. J Virol 89: 11630-11642. https://doi.org/10.1128/ JVI.01972-15.
234. Grondahl B, Ankermann T, von Bismarck P, Rockahr S, Kowalzik F, Gehring S, Meyer C, Knuf M, Puppe W. 2014. The 2009 pandemic influenza A(H1N1) coincides with changes in the epidemiology of other viral pathogens causing acute respiratory tract infections in children. Infection 42: 303-308. https://doi.org/10.1007/s15010-013-0545-5.
235. Weber MW, Mulholland EK, Greenwood BM. 1998. Respiratory syncytial virus infection in tropical and developing countries. Trop Med Int Health 3: 268-280. https://doi.org/10.1046/j.1365-3156.1998.00213.x.
236. Gamba-Sanchez N, Rodriguez-Martinez CE, Sossa-Briceno MP. 2016. Epidemic activity of respiratory syncytial virus is related to temperature and rainfall in equatorial tropical countries. Epidemiol Infect 144: 2057-2063. https://doi.org/10.1017/S0950268816000273.
237. Rodriguez-Martinez CE, Sossa-Briceno MP, Acuna-Cordero R. 2015. Relationship between meteorological conditions and respiratory syncytial virus in a tropical country. Epidemiol Infect 143: 2679-2686. https:// doi.org/10.1017/S0950268814003793.
238. Lowen AC, Mubareka S, Steel J, Palese P. 2007. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog 3: 1470-1476.
239. Zhang XL, Shao XJ, Wang J, Guo WL. 2013. Temporal characteristics of respiratory syncytial virus infection in children and its correlation with climatic factors at a public pediatric hospital in Suzhou. J Clin Virol 58: 666-670. https://doi.org/10.1016/j.jcv.2013.09.027.
240. Coates HV, Alling DW, Chanock RM. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 83: 299-313.
241. Anderson LJ, Hierholzer JC, Tsou C, Hendry RM, Fernie BF, Stone Y, McIntosh K. 1985. Antigenic characterization of respiratory syncytial virus strains with monoclonal antibodies. J Infect Dis 151: 626-633. https://doi.org/10.1093/infdis/151.4.626.
242. Jafri HS, Wu X, Makari D, Henrickson KJ. 2013. Distribution of respiratory syncytial virus subtypes A and B among infants presenting to the emergency department with lower respiratory tract infection or apnea. Pediatr Infect Dis J 32: 335-340. https://doi.org/10.1097/INF.0b013e318282603a.
243. Esposito S, Piralla A, Zampiero A, Bianchini S, Di Pietro G, Scala A, Pinzani R, Fossali E, Baldanti F, Principi N. 2015. Characteristics and their clinical relevance of respiratory syncytial virus types and genotypes circulating in northern Italy in five consecutive winter seasons. PLoS One 10: e0129369. https://doi.org/10.1371/journal.pone.0129369.
244. Peret TC, Hall CB, Schnabel KC, Golub JA, Anderson LJ. 1998. Circulation patterns of genetically distinct group A and B strains of human respiratory syncytial virus in a community. J Gen Virol 79: 2221-2229. https:// doi.org/10.1099/0022-1317-79-9-2221.
245. Hall CB, Walsh EE, Schnabel KC, Long CE, McConnochie KM, Hildreth SW, Anderson LJ. 1990. Occurrence of groups A and B of respiratory syncytial virus over 15 years: associated epidemiologic and clinical characteristics in hospitalized and ambulatory children. J Infect Dis 162: 1283-1290. https://doi.org/10.1093/infdis/162.6.1283.
246. White LJ, Waris M, Cane PA, Nokes DJ, Medley GF. 2005. The transmission dynamics of groups A and B human respiratory syncytial virus (hRSV) in England & Wales and Finland: seasonality and crossprotection. Epidemiol Infect 133: 279-289. https://doi.org/10.1017/ S0950268804003450.
247. Kim YI, Murphy R, Majumdar S, Harrison LG, Aitken J, DeVincenzo JP. 2015. Relating plaque morphology to respiratory syncytial virus subgroup, viral load, and disease severity in children. Pediatr Res 78: 380-388. https://doi.org/10.1038/pr.2015.122.
248. Hall CB, Douglas RG, Jr, Schnabel KC, Geiman JM. 1981. Infectivity of respiratory syncytial virus by various routes of inoculation. Infect Immun 33: 779-783.
249. Buchman CA, Doyle WJ, Pilcher O, Gentile DA, Skoner DP. 2002. Nasal and otologic effects of experimental respiratory syncytial virus infection in adults. Am J Otolaryngol 23: 70-75. https://doi.org/10.1053/ ajot.2002.30634.
250. Agoti CN, Otieno JR, Munywoki PK, Mwihuri AG, Cane PA, Nokes DJ, Kellam P, Cotten M. 2015. Local evolutionary patterns of human respiratory syncytial virus derived from whole-genome sequencing. J Virol 89: 3444-3454. https://doi.org/10.1128/JVI.03391-14.
251. Bose ME, He J, Shrivastava S, Nelson MI, Bera J, Halpin RA, Town CD, Lorenzi HA, Noyola DE, Falcone V, Gerna G, De Beenhouwer H, Videla C, Kok T, Venter M, Williams JV, Henrickson KJ. 2015. Sequencing and analysis of globally obtained human respiratory syncytial virus A and B genomes. PLoS One 10: e0120098. https://doi.org/10.1371/ journal.pone.0120098.
252. Grad YH, Newman R, Zody M, Yang X, Murphy R, Qu J, Malboeuf CM, Levin JZ, Lipsitch M, DeVincenzo J. 2014. Within-host whole-genome deep sequencing and diversity analysis of human respiratory syncytial virus infection reveals dynamics of genomic diversity in the absence and presence of immune pressure. J Virol 88: 7286-7293. https:// doi.org/10.1128/JVI.00038-14.
253. Schobel SA, Stucker KM, Moore ML, Anderson LJ, Larkin EK, Shankar J, Bera J, Puri V, Shilts MH, Rosas-Salazar C, Halpin RA, Fedorova N, Shrivastava S, Stockwell TB, Peebles RS, Hartert TV, Das SR. 2016. Respiratory syncytial virus whole-genome sequencing identifies convergent evolution of sequence duplication in the C-terminus of the G gene. Sci Rep 6: 26311. https://doi.org/10.1038/srep26311.
254. Ausar SF, Rexroad J, Frolov VG, Look JL, Konar N, Middaugh CR. 2005. Analysis of the thermal and pH stability of human respiratory syncytial virus. Mol Pharm 2: 491-499. https://doi.org/10.1021/mp0500465.
255. Foxman EF, Storer JA, Fitzgerald ME, Wasik BR, Hou L, Zhao H, Turner PE, Pyle AM, Iwasaki A. 2015. Temperature-dependent innate defense against the common cold virus limits viral replication at warm temperature in mouse airway cells. Proc Natl Acad Sci U S A 112: 827-832. https://doi.org/10.1073/pnas.1411030112.
256. Branche AR, Falsey AR. 2015. Respiratory syncytial virus infection in older adults: an under-recognized problem. Drugs Aging 32: 261-269. https://doi.org/10.1007/s40266-015-0258-9.
257. Prendergast C, Papenburg J. 2013. Rapid antigen-based testing for respiratory syncytial virus: moving diagnostics from bench to bedside? Future Microbiol 8: 435-444. https://doi.org/10.2217/fmb.13.9.
258. Walsh P, Overmyer C, Hancock C, Heffner J, Walker N, Nguyen T, Shanholtzer L, Caldera E, Pusavat J, Mordechai E, Adelson ME, Iacono KT. 2014. Is the interpretation of rapid antigen testing for respiratory syncytial virus as simple as positive or negative? Emerg Med J 31: 153-159. https://doi.org/10.1136/emermed-2013-202729.
259. Aslanzadeh J, Zheng X, Li H, Tetreault J, Ratkiewicz I, Meng S, Hamilton P, Tang YW. 2008. Prospective evaluation of rapid antigen tests for diagnosis of respiratory syncytial virus and human metapneumovirus infections. J Clin Microbiol 46: 1682-1685. https://doi.org/10.1128/ JCM.00008-08.
260. Ohm-Smith MJ, Nassos PS, Haller BL. 2004. Evaluation of the Binax NOW, BD Directigen, and BD Directigen EZ assays for detection of respiratory syncytial virus. J Clin Microbiol 42: 2996-2999. https:// doi.org/10.1128/JCM.42.7.2996-2999.2004.
261. US Food and Drug Administration. 21 October 2003. 510(k) substantial equivalence determination. Decision summary. Device only template. US Food and Drug Administration, Silver Spring, MD. http:// www.accessdata.fda.gov/cdrh_docs/reviews/K032166.pdf.
262. Casiano-Colon AE, Hulbert BB, Mayer TK, Walsh EE, Falsey AR. 2003. Lack of sensitivity of rapid antigen tests for the diagnosis of respiratory syncytial virus infection in adults. J Clin Virol 28: 169-174. https:// doi.org/10.1016/S1386-6532(03)00002-7.
263. Rabon-Stith KM, McGuiness CB, Saunders B, Edelman L, Kumar VR, Boron ML. 2013. Laboratory testing trends for respiratory syncytial virus, 2007-2011. J Clin Virol 58: 575-578. https://doi.org/10.1016/ j.jcv.2013.09.012.
264. Tuttle R, Weick A, Schwarz WS, Chen X, Obermeier P, Seeber L, Tief F, Muehlhans S, Karsch K, Peiser C, Duwe S, Schweiger B, Rath B. 2015. Evaluation of novel second-generation RSV and influenza rapid tests at the point of care. Diagn Microbiol Infect Dis 81: 171-176. https:// doi.org/10.1016/j.diagmicrobio.2014.11.013.
265. Schwartz RH, Selvarangan R, Zissman EN. 2015. BD Veritor system respiratory syncytial virus rapid antigen detection test: point-of-care results in primary care pediatric offices compared with reverse transcriptase polymerase chain reaction and viral culture methods. Pediatr Emerg Care 31: 830-834. https://doi.org/10.1097/ PEC.0000000000000371.
266. Kanwar N, Hassan F, Nguyen A, Selvarangan R. 2015. Head-to-head comparison of the diagnostic accuracies of BD Veritor System RSV and Quidel(R) Sofia(R) RSV FIA systems for respiratory syncytial virus (RSV) diagnosis. J Clin Virol 65: 83-86. https://doi.org/10.1016/j.jcv.2015.02.008.
267. Sautter RL, Thomson RB, Jr. 2015. Consolidated clinical microbiology laboratories. J Clin Microbiol 53: 1467-1472. https://doi.org/10.1128/ JCM.02569-14.
268. Zumla A, Al-Tawfiq JA, Enne VI, Kidd M, Drosten C, Breuer J, Muller MA, Hui D, Maeurer M, Bates M, Mwaba P, Al-Hakeem R, Gray G, Gautret P, Al-Rabeeah AA, Memish ZA, Gant V. 2014. Rapid point of care diagnostic tests for viral and bacterial respiratory tract infections-needs, advances, and future prospects. Lancet Infect Dis 14: 1123-1135. https:// doi.org/10.1016/S1473-3099(14)70827-8.
269. Moreira LP, Watanabe AS, Carraro E, da Silva ER, Guatura SB, Granato C, Bellei NJ. 2013. A survey strategy for human respiratory syncytial virus detection among haematopoietic stem cell transplant patients: epidemiological and methodological analysis. Mem Inst Oswaldo Cruz 108: 119-122. https://doi.org/10.1590/S0074-02762013000100021.
270. Rath B, Tief F, Obermeier P, Tuerk E, Karsch K, Muehlhans S, Adamou E, Duwe S, Schweiger B. 2012. Early detection of influenza A and B infection in infants and children using conventional and fluorescencebased rapid testing. J Clin Virol 55: 329-333. https://doi.org/10.1016/ j.jcv.2012.08.002.
271. Landry ML, Ferguson D. 2014. Comparison of Simplexa Flu A/B & RSV PCR with cytospin-immunofluorescence and laboratory-developed TaqMan PCR in predominantly adult hospitalized patients. J Clin Microbiol 52: 3057-3059. https://doi.org/10.1128/JCM.00738-14.
272. Shafik CF, Mohareb EW, Youssef FG. 2011. Comparison of direct fluorescence assay and real-time RT-PCR as diagnostics for respiratory syncytial virus in young children. J Trop Med 2011: 781919. https:// doi.org/10.1155/2011/781919.
273. US FDA. 6 January 2015. FDA grants first CLIA waiver for nucleic acid-based flu diagnostic test. US FDA, Silver Spring, MD. http:// www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm429127.htm.
274. Salez N, Nougairede A, Ninove L, Zandotti C, de Lamballerie X, Charrel RN. 2015. Prospective and retrospective evaluation of the Cepheid Xpert(R) Flu/RSV XC assay for rapid detection of influenza A, influenza B, and respiratory syncytial virus. Diagn Microbiol Infect Dis 81: 256-258. https://doi.org/10.1016/j.diagmicrobio.2015.01.008.
275. Douthwaite ST, Walker C, Adams EJ, Mak C, Vecino Ortiz A, Martinez-Alier N, Goldenberg SD. 2016. Performance of a novel point-of-care molecular assay for detection of influenza A and B viruses and respiratory syncytial virus (Enigma MiniLab) in children with acute respiratory infection. J Clin Microbiol 54: 212-215. https://doi.org/10.1128/ JCM.02887-15.
276. Goldenberg SD, Edgeworth JD. 2015. The Enigma ML FluAB-RSV assay: a fully automated molecular test for the rapid detection of influenza A, B and respiratory syncytial viruses in respiratory specimens. Expert Rev Mol Diagn 15: 23-32. https://doi.org/10.1586/14737159.2015.983477.
277. Selvaraju SB, Bambach AV, Leber AL, Patru MM, Patel A, Menegus MA. 2014. Comparison of the Simplexa Flu A/B & RSV kit (nucleic acid extraction-dependent assay) and the Prodessa ProFlu+ assay for detecting influenza and respiratory syncytial viruses. Diagn Microbiol Infect Dis 80: 50-52. https://doi.org/10.1016/j.diagmicrobio.2013.11.015.
278. Selvaraju SB, Tierney D, Leber AL, Patel A, Earley AK, Jaiswal D, Menegus MA. 2014. Influenza and respiratory syncytial virus detection in clinical specimens without nucleic acid extraction using FOCUS direct disc assay is substantially equivalent to the traditional methods and the FOCUS nucleic acid extraction-dependent RT-PCR assay. Diagn Microbiol Infect Dis 78: 232-236. https://doi.org/10.1016/j.diagmicrobio.2013.11.016.
279. de-Paris F, Beck C, Machado AB, Paiva RM, da Silva Menezes D, de Souza Nunes L, Kuchenbecker R, Barth AL. 2012. Optimization of one-step duplex real-time RT-PCR for detection of influenza and respiratory syncytial virus in nasopharyngeal aspirates. J Virol Methods 186: 189-192. https://doi.org/10.1016/j.jviromet.2012.07.008.
280. Shirato K, Nishimura H, Saijo M, Okamoto M, Noda M, Tashiro M, Taguchi F. 2007. Diagnosis of human respiratory syncytial virus infection using reverse transcription loop-mediated isothermal amplification. J Virol Methods 139: 78-84. https://doi.org/10.1016/j.jviromet.2006.09.014.
281. Burd EM. 2010. Validation of laboratory-developed molecular assays for infectious diseases. Clin Microbiol Rev 23: 550-576. https://doi.org/10.1128/CMR.00074-09.
282. Felder RA, Jackson KD, Walter AM. 2014. Process evaluation of an open architecture real-time molecular laboratory platform. J Lab Autom 19: 468-473. https://doi.org/10.1177/2211068214533195.
283. Bell JJ, Anderson EJ, Greene WH, Romero JR, Merchant M, Selvarangan R. 2014. Multicenter clinical performance evaluation of BD Veritor system for rapid detection of respiratory syncytial virus. J Clin Virol 61: 113-117. https://doi.org/10.1016/j.jcv.2014.05.020.
284. Wright PF, Ikizler MR, Gonzales RA, Carroll KN, Johnson JE, Werkhaven JA. 2005. Growth of respiratory syncytial virus in primary epithelial cells from the human respiratory tract. J Virol 79: 8651-8654. https://doi.org/10.1128/JVI.79.13.8651-8654.2005.
285. Smith MC, Creutz C, Huang YT. 1991. Detection of respiratory syncytial virus in nasopharyngeal secretions by shell vial technique. J Clin Microbiol 29: 463-465.
286. Matthey S, Nicholson D, Ruhs S, Alden B, Knock M, Schultz K, Schmuecker A. 1992. Rapid detection of respiratory viruses by shell vial culture and direct staining by using pooled and individual monoclonal antibodies. J Clin Microbiol 30: 540-544.
287. Pedneault L, Robillard L, Turgeon JP. 1994. Validation of respiratory syncytial virus enzyme immunoassay and shell vial assay results. J Clin Microbiol 32: 2861-2864.
288. Rabalais GP, Stout GG, Ladd KL, Cost KM. 1992. Rapid diagnosis of respiratory viral infections by using a shell vial assay and monoclonal antibody pool. J Clin Microbiol 30: 1505-1508.
289. Barenfanger J, Drake C, Mueller T, Troutt T, O’Brien J, Guttman K. 2001. R-Mix cells are faster, at least as sensitive and marginally more costly than conventional cell lines for the detection of respiratory viruses. J Clin Virol 22: 101-110. https://doi.org/10.1016/S1386-6532(01)00171-8.
290. Valdovinos MR, Gomez B. 2003. Establishment of respiratory syncytial virus persistence in cell lines: association with defective interfering particles. Intervirology 46: 190-198. https://doi.org/10.1159/000071461.
291. Halstead DC, Todd S, Fritch G. 1990. Evaluation of five methods for respiratory syncytial virus detection. J Clin Microbiol 28: 1021-1025.
292. Levitz R, Wattier R, Phillips P, Solomon A, Lawler J, Lazar I, Weibel C, Kahn JS. 2012. Induction of IL-6 and CCL5 (RANTES) in human respiratory epithelial (A549) cells by clinical isolates of respiratory syncytial virus is strain specific. Virol J 9: 190. https://doi.org/10.1186/1743-422X-9-190.
293. Meziere A, Mollat C, Lapied R, Billaudel S, Courtieu AL. 1990. Detection of respiratory syncytial virus antigen after seventy-two hours of culture. J Med Virol 31: 241-244. https://doi.org/10.1002/jmv.1890310312.
294. Cho CH, Lee CK, Nam MH, Yoon SY, Lim CS, Cho Y, Kim YK. 2014. Evaluation of the AdvanSure real-time RT-PCR compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses. Diagn Microbiol Infect Dis 79: 14-18. https://doi.org/10.1016/ j.diagmicrobio.2014.01.016.
295. Cho CH, Chulten B, Lee CK, Nam MH, Yoon SY, Lim CS, Cho Y, Kim YK. 2013. Evaluation of a novel real-time RT-PCR using TOCE technology compared with culture and Seeplex RV15 for simultaneous detection of respiratory viruses. J Clin Virol 57: 338-342. https://doi.org/10.1016/ j.jcv.2013.04.014.
296. Kadmon G, Levy I, Mandelboim M, Nahum E, Stein J, Dovrat S, Schonfeld T. 2013. Polymerase-chain-reaction-based diagnosis of viral pulmonary infections in immunocompromised children. Acta Paediatr 102: e263-e268. https://doi.org/10.1111/apa.12207.
297. Deng J, Ma Z, Huang W, Li C, Wang H, Zheng Y, Zhou R, Tang YW. 2013. Respiratory virus multiplex RT-PCR assay sensitivities and influence factors in hospitalized children with lower respiratory tract infections. Virol Sin 28: 97-102. https://doi.org/10.1007/s12250-013-3312-y.
298. Hawkinson D, Abhyankar S, Aljitawi O, Ganguly S, McGuirk JP, Horvat R. 2013. Delayed RSV diagnosis in a stem cell transplant population due to mutations that result in negative polymerase chain reaction. Diagn Microbiol Infect Dis 75: 426-430. https://doi.org/10.1016/ j.diagmicrobio.2012.12.014.
299. Lundin A, Bergstrom T, Trybala E. 2013. Screening and evaluation of anti-respiratory syncytial virus compounds in cultured cells. Methods Mol Biol 1030: 345-363. https://doi.org/10.1007/978-1-62703-484-5_27.
300. Kwanten L, De Clerck B, Roymans D. 2013. A fluorescence-based highthroughput antiviral compound screening assay against respiratory syncytial virus. Methods Mol Biol 1030: 337-344. https://doi.org/10.1007/978-1-62703-484-5_26.
301. Thevenin T, Lobert PE, Dewilde A, Hober D. 2012. A respiratory syncytial virus isolate enables the testing of virucidal products. Int J Hyg Environ Health 215: 293-296. https://doi.org/10.1016/j.ijheh.2011.10.001.
302. Li L, Deng X, Mee ET, Collot-Teixeira S, Anderson R, Schepelmann S, Minor PD, Delwart E. 2015. Comparing viral metagenomics methods using a highly multiplexed human viral pathogens reagent. J Virol Methods 213: 139-146. https://doi.org/10.1016/j.jviromet.2014.12.002.
303. Prachayangprecha S, Schapendonk CM, Koopmans MP, Osterhaus AD, Schurch AC, Pas SD, van der Eijk AA, Poovorawan Y, Haagmans BL, Smits SL. 2014. Exploring the potential of next-generation sequencing in detection of respiratory viruses. J Clin Microbiol 52: 3722-3730. https://doi.org/10.1128/JCM.01641-14.
304. Ge F, Parker J, Chul Choi S, Layer M, Ross K, Jilly B, Chen J. 2015. Preferential amplification of pathogenic sequences. Sci Rep 5: 11047. https://doi.org/10.1038/srep11047.
305. Naccache SN, Peggs KS, Mattes FM, Phadke R, Garson JA, Grant P, Samayoa E, Federman S, Miller S, Lunn MP, Gant V, Chiu CY. 2015. Diagnosis of neuroinvasive astrovirus infection in an immunocompromised adult with encephalitis by unbiased next-generation sequencing. Clin Infect Dis 60: 919-923. https://doi.org/10.1093/cid/ciu912.
306. Yang J, Yang F, Ren L, Xiong Z, Wu Z, Dong J, Sun L, Zhang T, Hu Y, Du J, Wang J, Jin Q. 2011. Unbiased parallel detection of viral pathogens in clinical samples by use of a metagenomic approach. J Clin Microbiol 49: 3463-3469. https://doi.org/10.1128/JCM.00273-11.
307. Cotten M, Lam TT, Watson SJ, Palser AL, Petrova V, Grant P, Pybus OG, Rambaut A, Guan Y, Pillay D, Kellam P, Nastouli E. 2013. Full-genome deep sequencing and phylogenetic analysis of novel human betacoronavirus. Emerg Infect Dis 19: 736-742. https://doi.org/10.3201/ eid1905.130057.
308. Somerville LK, Ratnamohan VM, Dwyer DE, Kok J. 2015. Molecular diagnosis of respiratory viruses. Pathology 47: 243-249. https://doi.org/10.1097/PAT.0000000000000240.
309. Dudas RA, Karron RA. 1998. Respiratory syncytial virus vaccines. Clin Microbiol Rev 11: 430-439.
310. Murphy BR, Walsh EE. 1988. Formalin-inactivated respiratory syncytial virus vaccine induces antibodies to the fusion glycoprotein that are deficient in fusion-inhibiting activity. J Clin Microbiol 26: 1595-1597.
311. Moghaddam A, Olszewska W, Wang B, Tregoning JS, Helson R, Sattentau QJ, Openshaw PJ. 2006. A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines. Nat Med 12: 905-907. https://doi.org/10.1038/nm1456.
312. Schmidt MR, McGinnes-Cullen LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. 2014. Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory. J Virol 88: 10165-10176. https://doi.org/10.1128/JVI.01250-14.
313. Paradiso PR, Hildreth SW, Hogerman DA, Speelman DJ, Lewin EB, Oren J, Smith DH. 1994. Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old. Pediatr Infect Dis J 13: 792-798. https://doi.org/10.1097/00006454-199409000-00008.
314. Welliver RC, Tristram DA, Batt K, Sun M, Hogerman D, Hildreth S. 1994. Respiratory syncytial virus-specific cell-mediated immune responses after vaccination with a purified fusion protein subunit vaccine. J Infect Dis 170: 425-428. https://doi.org/10.1093/infdis/170.2.425.
315. Power UF, Nguyen TN, Rietveld E, de Swart RL, Groen J, Osterhaus AD, de Groot R, Corvaia N, Beck A, Bouveret-Le-Cam N, Bonnefoy JY. 2001. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J Infect Dis 184: 1456-1460. https://doi.org/10.1086/324426.
316. Gonzalez IM, Karron RA, Eichelberger M, Walsh EE, Delagarza VW, Bennett R, Chanock RM, Murphy BR, Clements-Mann ML, Falsey AR. 2000. Evaluation of the live attenuated cpts 248/404 RSV vaccine in combination with a subunit RSV vaccine (PFP-2) in healthy young and older adults. Vaccine 18: 1763-1772. https://doi.org/10.1016/S0264-410X(99)00527-7.
317. Falsey AR, Walsh EE. 1996. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14: 1214-1218. https://doi.org/10.1016/S0264-410X(96)00030-8.
318. Piedra PA, Grace S, Jewell A, Spinelli S, Bunting D, Hogerman DA, Malinoski F, Hiatt PW. 1996. Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis. Pediatr Infect Dis J 15: 23-31. https://doi.org/10.1097/00006454-199601000-00006.
319. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. 1998. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J Infect Dis 177: 467-469. https://doi.org/10.1086/517377.
320. Olmsted RA, Elango N, Prince GA, Murphy BR, Johnson PR, Moss B, Chanock RM, Collins PL. 1986. Expression of the F glycoprotein of respiratory syncytial virus by a recombinant vaccinia virus: comparison of the individual contributions of the F and G glycoproteins to host immunity. Proc Natl Acad Sci U S A 83: 7462-7466. https://doi.org/10.1073/pnas.83.19.7462.
321. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108: 9619-9624. https://doi.org/10.1073/pnas.1106536108.
322. Welliver RC, Sr, Papin J, Wolf R, Ivanov V, Moore S, Raghunadan R, Lu H, Flyer D, Smith G, Glenn G. 2014. Immunization of pregnant baboons with the RSV F nanoparticle vaccine protects infant baboons challenged with respiratory syncytial virus in a comparable manner to infants prophylaxed with palivizumab. Abstr 54th Intersci Conf Antimicrob Agents Chemother, abstr I-649.
323. Garg R, Latimer L, Wang Y, Simko E, Gerdts V, Potter A, van Drunen Littel-van den Hurk S. 2016. Maternal immunization with respiratory syncytial virus fusion protein formulated with a novel combination adjuvant provides protection from RSV in newborn lambs. Vaccine 34: 261-269. https://doi.org/10.1016/j.vaccine.2015.11.029.
324. Schmidt MR, McGinnes LW, Kenward SA, Willems KN, Woodland RT, Morrison TG. 2012. Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains. J Virol 86: 11654-11662. https://doi.org/10.1128/JVI.01510-12.
325. Conrad DA, Christenson JC, Waner JL, Marks MI. 1987. Aerosolized ribavirin treatment of respiratory syncytial virus infection in infants hospitalized during an epidemic. Pediatr Infect Dis J 6: 152-158. https:// doi.org/10.1097/00006454-198702000-00003.
326. Hall CB, Walsh EE, Hruska JF, Betts RF, Hall WJ. 1983. Ribavirin treatment of experimental respiratory syncytial viral infection. A controlled double-blind study in young adults. JAMA 249: 2666-2670.
327. Smith DW, Frankel LR, Mathers LH, Tang AT, Ariagno RL, Prober CG. 1991. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection. N Engl J Med 325: 24-29. https://doi.org/10.1056/ NEJM199107043250105.
328. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G, Committee BS. 2001. Factors influencing ribavirin-induced hemolysis. J Hepatol 34: 911-916. https://doi.org/10.1016/S0168-8278(01)00029-0.
329. Martin JT, Kugler JD, Gumbiner CH, Brown JC, Murphy KR, Colombo JL, McManus BM. 1990. Refractory congestive heart failure after ribavirin in infants with heart disease and respiratory syncytial virus. Nebr Med J 75: 23-26.
330. Kilham L, Ferm VH. 1977. Congenital anomalies induced in hamster embryos with ribavirin. Science 195: 413-414. https://doi.org/10.1126/ science.401547.
331. Kochhar DM, Penner JD, Knudsen TB. 1980. Embryotoxic, teratogenic, and metabolic effects of ribavirin in mice. Toxicol Appl Pharmacol 52: 99-112. https://doi.org/10.1016/0041-008X(80)90252-5.
332. Arnold SD, Alonso R. 1993. Ribavirin aerosol: methods for reducing employee exposure. AAOHN J 41: 382-392.
333. Kacmarek RM, Kratohvil J. 1992. Evaluation of a double-enclosure double-vacuum unit scavenging system for ribavirin administration. Respir Care 37: 37-45.
334. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, Tristram DA, Siber GR, Prince GA, Van Raden M, Hemming VG, Respiratory Syncytial Virus Immune Globulin Study Group. 1993. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 329: 1524-1530.
335. Groothuis JR, Levin MJ, Rodriguez W, Hall CB, Long CE, Kim HW, Lauer BA, Hemming VG. 1991. Use of intravenous gamma globulin to passively immunize high-risk children against respiratory syncytial virus: safety and pharmacokinetics. The RSVIG Study Group. Antimicrob Agents Chemother 35: 1469-1473. https://doi.org/10.1128/ AAC.35.7.1469.
336. Anonymous. 1997. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group. Pediatrics 99: 93-99.
337. Wasserman RL, Lumry W, Harris J, III, Levy R, Stein M, Forbes L, Cunningham-Rundles C, Melamed I, Kobayashi AL, Du W, Kobayashi R. 2016. Efficacy, safety, and pharmacokinetics of a new 10% liquid intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses in subjects with primary immunodeficiency disease. J Clin Immunol 36: 590-599. https://doi.org/10.1007/ s10875-016-0308-z.
338. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sanchez PJ, Steichen J, Givner LB, Jennings TL, Top FH, Jr, Carlin D, Connor E. 1998. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 17: 110-115. https://doi.org/10.1097/00006454-199802000-00006.
339. Van Heeke G, Allosery K, De Brabandere V, De Smedt T, Detalle L, de Fougerolles A. 29 June 2016. Nanobodies as inhaled biotherapeutics for lung diseases. Pharmacol Ther https://doi.org/10.1016/j.pharmthera.2016.06.012.
340. Detalle L, Stohr T, Palomo C, Piedra PA, Gilbert BE, Mas V, Millar A, Power UF, Stortelers C, Allosery K, Melero JA, Depla E. 2015. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother 60: 6-13. https://doi.org/10.1128/AAC.01802-15.
341. De Bruyn S, De Smedt T, Allosery K, Crabbe P, De Brabandere V, Detalle L, Mortier K, Schoolmeester A, Wouters H, Stöhr T, Depla E. 2015. ALX-0171: safety and therapeutic potential of an inhaled anti-RSV nanobody. RDD Europe 2015 1: 37-48.
342. Zhao X, Sullender WM. 2005. In vivo selection of respiratory syncytial viruses resistant to palivizumab. J Virol 79: 3962-3968. https://doi.org/10.1128/JVI.79.7.3962-3968.2005.
343. Zhao X, Chen FP, Megaw AG, Sullender WM. 2004. Variable resistance to palivizumab in cotton rats by respiratory syncytial virus mutants. J Infect Dis 190: 1941-1946. https://doi.org/10.1086/425515.
344. Zhu Q, McAuliffe JM, Patel NK, Palmer-Hill FJ, Yang CF, Liang B, Su L, Zhu W, Wachter L, Wilson S, MacGill RS, Krishnan S, McCarthy MP, Losonsky GA, Suzich JA. 2011. Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. J Infect Dis 203: 674-682. https://doi.org/10.1093/infdis/jiq100.
345. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, Stevens RC. 1997. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 119: 681-690. https://doi.org/10.1021/ ja963036t.
346. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, Heneghan CJ. 2014. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 4: CD008965. https://doi.org/10.1002/14651858.CD008965.pub4.
347. Simoes EA, DeVincenzo JP, Boeckh M, Bont L, Crowe JE, Jr, Griffiths P, Hayden FG, Hodinka RL, Smyth RL, Spencer K, Thirstrup S, Walsh EE, Whitley RJ. 2015. Challenges and opportunities in developing respiratory syncytial virus therapeutics. J Infect Dis 211(Suppl 1): S1-S20. https://doi.org/10.1093/infdis/jiu828.
348. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, Ramanathan S, O’Riordan T, Lewis SA, Li X, Toback SL, Lin SL, Chien JW. 2014. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371: 711-722. https://doi.org/10.1056/NEJMoa1401184.
349. Vrang L, Bazin H, Remaud G, Chattopadhyaya J, Oberg B. 1987. Inhibition of the reverse transcriptase from HIV by 3=-azido-3=-deoxythymidine triphosphate and its threo analogue. Antiviral Res 7: 139-149. https://doi.org/10.1016/0166-3542(87)90002-7.
350. Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O’Boyle DR, II, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. 2010. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 465: 96-100. https://doi.org/10.1038/ nature08960.
351. Noton SL, Fearns R. 2015. Initiation and regulation of paramyxovirus transcription and replication. Virology 479-480: 545-554. https:// doi.org/10.1016/j.virol.2015.01.014.
352. Wang G, Deval J, Hong J, Dyatkina N, Prhavc M, Taylor J, Fung A, Jin Z, Stevens SK, Serebryany V, Liu J, Zhang Q, Tam Y, Chanda SM, Smith DB, Symons JA, Blatt LM, Beigelman L. 2015. Discovery of 4=-chloromethyl-2=-deoxy-3=,5=-di-O-isobutyryl-2=-fluorocytidine (ALS-8176), a first-inclass RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 58: 1862-1878. https://doi.org/10.1021/jm5017279.
353. McKenzie R, Fried MW, Sallie R, Conjeevaram H, Di Bisceglie AM, Park Y, Savarese B, Kleiner D, Tsokos M, Luciano C, Pruett T, Stotka JL, Straus SE, Hoofnagle JH. 1995. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N Engl J Med 333: 1099-1105. https://doi.org/10.1056/NEJM199510263331702.
354. Clarke MO, Mackman R, Byun D, Hui H, Barauskas O, Birkus G, Chun BK, Doerffler E, Feng J, Karki K, Lee G, Perron M, Siegel D, Swaminathan S, Lee W. 2015. Discovery of beta-D-2=-deoxy-2=-alpha-fluoro-4=-alphacyano-5-aza-7,9-dideaza adenosine as a potent nucleoside inhibitor of respiratory syncytial virus with excellent selectivity over mitochondrial RNA and DNA polymerases. Bioorg Med Chem Lett 25: 2484-2487. https://doi.org/10.1016/j.bmcl.2015.04.073.
355. Vanheule V, Vervaeke P, Mortier A, Noppen S, Gouwy M, Snoeck R, Andrei G, Van Damme J, Liekens S, Proost P. 2016. Basic chemokinederived glycosaminoglycan binding peptides exert antiviral properties against dengue virus serotype 2, herpes simplex virus-1 and respiratory syncytial virus. Biochem Pharmacol 100: 73-85. https://doi.org/10.1016/ j.bcp.2015.11.001.
356. Hendricks GL, Velazquez L, Pham S, Qaisar N, Delaney JC, Viswanathan K, Albers L, Comolli JC, Shriver Z, Knipe DM, Kurt-Jones EA, Fygenson DK, Trevejo JM, Wang JP, Finberg RW. 2015. Heparin octasaccharide decoy liposomes inhibit replication of multiple viruses. Antiviral Res 116: 34-44. https://doi.org/10.1016/j.antiviral.2015.01.008.
357. Li CM, Zheng LL, Yang XX, Wan XY, Wu WB, Zhen SJ, Li YF, Luo LF, Huang CZ. 2016. DNA-AuNP networks on cell membranes as a protective barrier to inhibit viral attachment, entry and budding. Biomaterials 77: 216-226. https://doi.org/10.1016/j.biomaterials.2015.11.008.
358. Vargas JE, Puga R, de Faria Poloni J, Saraiva Macedo Timmers LF, Porto BN, Norberto de Souza O, Bonatto D, Condessa Pitrez PM, Tetelbom Stein R. 2015. A network flow approach to predict protein targets and flavonoid backbones to treat respiratory syncytial virus infection. Biomed Res Int 2015: 301635. https://doi.org/10.1155/2015/301635.
359. Ginocchio CC, Swierkosz E, McAdam AJ, Marcon M, Storch GA, Valsamakis A, Juretschko S, Romero J, Yen-Lieberman B. 2010. Multicenter study of clinical performance of the 3M rapid detection RSV test. J Clin Microbiol 48: 2337-2343. https://doi.org/10.1128/JCM.00130-10.
360. Selvarangan R, Abel D, Hamilton M. 2008. Comparison of BD Directigen EZ RSV and Binax NOW RSV tests for rapid detection of respiratory syncytial virus from nasopharyngeal aspirates in a pediatric population. Diagn Microbiol Infect Dis 62: 157-161. https://doi.org/10.1016/ j.diagmicrobio.2008.05.005.
361. Liao RS, Tomalty LL, Majury A, Zoutman DE. 2009. Comparison of viral isolation and multiplex real-time reverse transcription-PCR for confirmation of respiratory syncytial virus and influenza virus detection by antigen immunoassays. J Clin Microbiol 47: 527-532. https://doi.org/10.1128/JCM.01213-08.
362. Jonckheere S, Verfaillie C, Boel A, Van Vaerenbergh K, Vanlaere E, Vankeerberghen A, De Beenhouwer H. 2015. Multicenter evaluation of BD Veritor System and RSV K-SeT for rapid detection of respiratory syncytial virus in a diagnostic laboratory setting. Diagn Microbiol Infect Dis 83: 37-40. https://doi.org/10.1016/j.diagmicrobio.2015.05.012.
363. Piche-Renaud PP, Turcot J, Chartrand C, Gravel J, Labrecque M, Vallieres E, Renaud C. 2016. Evaluation of a fluorescent immunoassay rapid test (Sofia) for detection of influenza A+B and RSV in a tertiary pediatric setting. Diagn Microbiol Infect Dis 84: 304-308. https://doi.org/10.1016/ j.diagmicrobio.2015.10.025.
364. Gharabaghi F, Hawan A, Drews SJ, Richardson SE. 2011. Evaluation of multiple commercial molecular and conventional diagnostic assays for the detection of respiratory viruses in children. Clin Microbiol Infect 17: 1900-1906. https://doi.org/10.1111/j.1469-0691.2011.03529.x.
365. Popowitch EB, Miller MB. 2015. Performance characteristics of Xpert Flu/RSV XC assay. J Clin Microbiol 53: 2720-2721. https://doi.org/10.1128/JCM.00972-15.
366. Gadsby NJ, Hardie A, Claas EC, Templeton KE. 2010. Comparison of the Luminex respiratory virus panel fast assay with in-house real-time PCR for respiratory viral infection diagnosis. J Clin Microbiol 48: 2213-2216. https://doi.org/10.1128/JCM.02446-09.
367. Yang XX, Li CM, Huang CZ. 2016. Curcumin modified silver nanoparticles for highly efficient inhibition of respiratory syncytial virus infection. Nanoscale 8: 3040-3048. https://doi.org/10.1039/C5NR07918G.
368. Liu Z, Ma N, Zhong Y, Yang ZQ. 2015. Antiviral effect of emodin from Rheum palmatum against coxsackievirus B5 and human respiratory syncytial virus in vitro. J Huazhong Univ Sci Technol Med Sci 35: 916-922. https://doi.org/10.1007/s11596-015-1528-9.
369. Ouizougun-Oubari M, Pereira N, Tarus B, Galloux M, Lassoued S, Fix J, Tortorici MA, Hoos S, Baron B, England P, Desmaele D, Couvreur P, Bontems F, Rey FA, Eleouet JF, Sizun C, Slama-Schwok A, Duquerroy S. 2015. A druggable pocket at the nucleocapsid/phosphoprotein interaction site of human respiratory syncytial virus. J Virol 89: 11129-11143. https://doi.org/10.1128/JVI.01612-15.
370. Perron M, Stray K, Kinkade A, Theodore D, Lee G, Eisenberg E, Sangi M, Gilbert BE, Jordan R, Piedra PA, Toms GL, Mackman R, Cihlar T. 2015. GS-5806 inhibits a broad range of respiratory syncytial virus clinical isolates by blocking the virus-cell fusion process. Antimicrob Agents Chemother 60: 1264-1273. https://doi.org/10.1128/AAC.01497-15.
371. Samuel D, Xing W, Niedziela-Majka A, Wong JS, Hung M, Brendza KM, Perron M, Jordan R, Sperandio D, Liu X, Mackman R, Sakowicz R. 2015. GS-5806 inhibits pre-to postfusion conformational changes of the respiratory syncytial virus fusion protein. Antimicrob Agents Chemother 59: 7109-7112. https://doi.org/10.1128/AAC.00761-15.